{"finance": {"result": {"symbol": "MRK", "instrumentInfo": {"technicalEvents": {"provider": "Trading Central", "sector": "Healthcare", "shortTermOutlook": {"stateDescription": "Bearish events outweigh bullish events.", "direction": "Bearish", "score": 2, "scoreDescription": "Bearish Evidence", "sectorDirection": "Bearish", "sectorScore": 4, "sectorScoreDescription": "Very Strong Bearish Evidence", "indexDirection": "Bearish", "indexScore": 2, "indexScoreDescription": "Bearish Evidence"}, "intermediateTermOutlook": {"stateDescription": "Recent bullish events outweigh bearish events.", "direction": "Bullish", "score": 2, "scoreDescription": "Bullish Evidence", "sectorDirection": "Bearish", "sectorScore": 3, "sectorScoreDescription": "Strong Bearish Evidence", "indexDirection": "Bearish", "indexScore": 2, "indexScoreDescription": "Bearish Evidence"}, "longTermOutlook": {"stateDescription": "All events are bearish.", "direction": "Bearish", "score": 2, "scoreDescription": "Bearish Evidence", "sectorDirection": "Bearish", "sectorScore": 1, "sectorScoreDescription": "Weak Bearish Evidence", "indexDirection": "Bearish", "indexScore": 2, "indexScoreDescription": "Bearish Evidence"}}, "keyTechnicals": {"provider": "Trading Central", "support": 85.73, "resistance": 102.71, "stopLoss": 82.039693}, "valuation": {"color": 1.0, "description": "Undervalued", "discount": "14%", "relativeValue": "Discount", "provider": "Trading Central"}}, "companySnapshot": {"sectorInfo": "Healthcare", "company": {"innovativeness": 0.9834, "hiring": 0.9039, "sustainability": 0.2095, "insiderSentiments": 0.9375, "earningsReports": 0.8875, "dividends": 0.7712}, "sector": {"innovativeness": 0.5, "hiring": 0.5, "sustainability": 0.5, "insiderSentiments": 0.5, "earningsReports": 0.5, "dividends": 0.5}}, "recommendation": {"targetPrice": 110.0, "provider": "Argus Research", "rating": "BUY"}, "upsell": {"msBullishSummary": ["Keytruda looks best positioned in the immuno-oncology landscape, buoyed by a first-mover advantage in the important indication of first-line non-small cell lung cancer.", "The growth in Merck's high margin cancer drugs should help expand the company's overall operating margin.", "Merck supports a strong dividend yield that looks secure based on a wide diversified portfolio of drugs."], "msBearishSummary": ["Outside of immuno oncology, Merck needs to increase the number of late-stage pipeline drugs.", "The eventual US patent loss on Keytruda in 2028 is concerning given the high sales contribution of the drug.", "Advancements in oncology can happen quickly, which could cause disruption to Merck's leading growth driver, Keytruda."], "companyName": "Merck & Company, Inc.", "msBullishBearishSummariesPublishDate": 1739480067000, "upsellReportType": "MORNINGSTAR_ANALYST"}, "upsellSearchDD": {"researchReports": {"reportId": "ARGUS_3209_AnalystReport_1742403690000", "provider": "Argus", "title": "BUY as company advances pipeline and on new approvals", "reportDate": "2025-03-19T17:01:30Z", "summary": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.", "investmentRating": "Bullish"}}, "events": [{"eventType": "Commodity Channel Index", "pricePeriod": "D", "tradingHorizon": "S", "tradeType": "S", "imageUrl": "https://s.yimg.com/uc/fin/img/assets/generic.svg", "startDate": 1742909400, "endDate": 1742909400}], "reports": [{"id": "3209_Analyst Report_1742403690000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2025-03-19T17:01:30Z", "reportTitle": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.", "targetPrice": 110.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500."}, {"id": "42982_Market Update_1742402790000", "headHtml": "Market Update: AEE, TT, MRK, NVDA", "provider": "Argus Research", "reportDate": "2025-03-19T16:46:30Z", "reportTitle": "The markets are higher at midday. Today is a Fed Day. At 2pm, the Fed announces its latest rate decision. No move is expected. At 2:30pm, Chairman Jerome Powell will hold his usual press conference and will answer questions. This quarter, the 'dot plot' also comes out which shows the Fed's leaning on the future direction of rates. The yield on the 10-year Treasury note is at 4.31%. Oil is at $67 per barrel. Bitcoin is near $84,300.", "tickers": ["TT", "AEE", "NVDA", "MRK"], "title": "The markets are higher at midday. Today is a Fed Day. At 2pm, the Fed announces its latest rate decision. No move is expected. At 2:30pm, Chairman Jerome Powell will hold his usual press conference and will answer questions. This quarter, the 'dot plot' also comes out which shows the Fed's leaning on the future direction of rates. The yield on the 10-year Treasury note is at 4.31%. Oil is at $67 per barrel. Bitcoin is near $84,300."}, {"id": "42617_Stock Picks_1739190710000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2025-02-10T12:31:50Z", "reportTitle": "Argus has identified 10 Investment Themes for 2025. This week, we take a deep dive into Theme 10, Pharmaceuticals and Biotechnology. With the aging U.S. population, the use of medications and medical technology is rising. The number of medications dispensed increased about 60% from 2012 to 2022, according to Statista. With the aging Baby Boomers cohort and the increasing percentage of the population over the age of 65, the rate is expected to go up. Analysts estimate that nine out of 10 elderly adults take prescription medication and more than half take four or more prescriptions. While the elderly represent the majority of the prescription market, those under the age of 65 are also taking more medications than ever as treatments become available for chronic and rare diseases. Blockbuster drugs also contribute to the escalating use of prescriptions. The market for GLP-1 medications used for weight loss and diabetes reached $47 billion in 2024 and is projected to reach $150 billion by 2030, according to market research firm MarketsandMarkets. Similarly, the global Alzheimer's market was at $8 billion in 2024 and is expected to grow at a 5% compounded annually growth rate through 2032. Over the coming years, the industry will continue to face headwinds from patent expirations on key drugs. A growing number of Big Pharma companies have turned to AI for drug development to boost revenue streams. Medtech is another growth sector within Healthcare. Doctors increasingly are using robotics and sophisticated and evolving medical devices to enhance quality of life. This week's list is a collaboration from our Healthcare team. Here are some companies on the Argus BUY list that our analysts believe are poised to benefit.", "tickers": ["SYK", "BSX", "NVO", "MRK", "VRTX", "UTHR", "UNH", "DHR", "IQV", "AZN", "GEHC", "LLY", "INCY", "GILD", "TEVA", "ISRG", "SNY"], "title": "Argus has identified 10 Investment Themes for 2025. This week, we take a deep dive into Theme 10, Pharmaceuticals and Biotechnology. With the aging U.S. population, the use of medications and medical technology is rising. The number of medications dispensed increased about 60% from 2012 to 2022, according to Statista. With the aging Baby Boomers cohort and the increasing percentage of the population over the age of 65, the rate is expected to go up. Analysts estimate that nine out of 10 elderly adults take prescription medication and more than half take four or more prescriptions. While the elderly represent the majority of the prescription market, those under the age of 65 are also taking more medications than ever as treatments become available for chronic and rare diseases. Blockbuster drugs also contribute to the escalating use of prescriptions. The market for GLP-1 medications used for weight loss and diabetes reached $47 billion in 2024 and is projected to reach $150 billion by 2030, according to market research firm MarketsandMarkets. Similarly, the global Alzheimer's market was at $8 billion in 2024 and is expected to grow at a 5% compounded annually growth rate through 2032. Over the coming years, the industry will continue to face headwinds from patent expirations on key drugs. A growing number of Big Pharma companies have turned to AI for drug development to boost revenue streams. Medtech is another growth sector within Healthcare. Doctors increasingly are using robotics and sophisticated and evolving medical devices to enhance quality of life. This week's list is a collaboration from our Healthcare team. Here are some companies on the Argus BUY list that our analysts believe are poised to benefit."}, {"id": "42609_Top/Bottom Insider Activity_1739187202000", "headHtml": "Daily \u2013 Vickers Top Buyers & Sellers for 02/10/2025", "provider": "Argus Research", "reportDate": "2025-02-10T11:33:22Z", "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.", "tickers": ["PBF", "V", "MRK", "LLY", "LFUS", "INSM", "TEM", "KEY"], "title": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions."}, {"id": "42377_Portfolio Ideas_1736949864000", "headHtml": "Portfolio Selector for January, 2025", "provider": "Argus Research", "reportDate": "2025-01-15T14:04:24Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Illumina Inc (ILMN); United Airlines Holdings Inc (UAL); Toll Brothers Inc. (TOL); Morgan Stanley (MS) and the Focus List deletions are AECOM (ACM); Dicks Sporting Goods, Inc. (DKS); Goldman Sachs Group, Inc. (GS); Merck & Co Inc (MRK).", "tickers": ["TOL", "UAL", "ILMN", "MS", "MRK", "ACM", "GS", "DKS"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Illumina Inc (ILMN); United Airlines Holdings Inc (UAL); Toll Brothers Inc. (TOL); Morgan Stanley (MS) and the Focus List deletions are AECOM (ACM); Dicks Sporting Goods, Inc. (DKS); Goldman Sachs Group, Inc. (GS); Merck & Co Inc (MRK)."}, {"id": "42292_Stock Picks_1736167002000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2025-01-06T12:36:42Z", "reportTitle": "Are there stock gems hiding in plain sight? Last week, we profiled Shooting Stars and Fallen Angels from 2024. This week, we look ahead, seeking possible hidden treasure in the form of large, undervalued stocks. Why is this cluster interesting to us? Mega-cap stocks usually are well-known entities and have proven their worth as both value and growth stocks. Often, they are resilient companies, with experienced management teams that have weathered a variety of storms and have come out stronger. Over time, they have delivered high performance, therefore building a track record. We like monitoring this group to uncover any undervalued gems. To gather our list of companies this week, we used the Argus Research Screening Tool with the following criteria: stocks must be on the Argus BUY list, have a market cap over $200 billion, and currently trading below their 52-week high. We note that many sectors are represented, but Healthcare shows up the most. Below are the top 20 Argus universe companies that fit this criteria.", "tickers": ["CVX", "KO", "NVO", "JNJ", "MRK", "ORCL", "ABBV", "ACN", "UNH", "DIS", "ASML", "MSFT", "TMUS", "TSLA", "AZN", "WFC", "XOM", "LLY", "HD", "CRM"], "title": "Are there stock gems hiding in plain sight? Last week, we profiled Shooting Stars and Fallen Angels from 2024. This week, we look ahead, seeking possible hidden treasure in the form of large, undervalued stocks. Why is this cluster interesting to us? Mega-cap stocks usually are well-known entities and have proven their worth as both value and growth stocks. Often, they are resilient companies, with experienced management teams that have weathered a variety of storms and have come out stronger. Over time, they have delivered high performance, therefore building a track record. We like monitoring this group to uncover any undervalued gems. To gather our list of companies this week, we used the Argus Research Screening Tool with the following criteria: stocks must be on the Argus BUY list, have a market cap over $200 billion, and currently trading below their 52-week high. We note that many sectors are represented, but Healthcare shows up the most. Below are the top 20 Argus universe companies that fit this criteria."}, {"id": "41927_Stock Picks_1732539683000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2024-11-25T13:01:23Z", "reportTitle": "Volatility in the stock market during the third quarter gave institutional investors a chance to buy the dips. Taking a look at 13F filings from well-known institutional portfolios, we see that the big guns were busy adding new companies to their portfolios or expanding existing holdings. Buying occurred across a range of sectors. Vickers Stock Research, a subsidiary of Argus Research Group, analyzes insider trading and institutional stock ownership. Form 13-Fs, which institutions must file to report their holdings, are due 45 days after the end of calendar quarters and have come in for 3Q24. We review 13Fs of major institutional investors, including activists, to see what they are buying and to look for trends. Activist investing is now less about generating a short-term return and more about achieving long-term returns through an active management/investor partnerships. Based on data from Vickers, the following is a list of select purchases made in the third quarter by some high-profile money managers, including the Argus Research investment ratings.", "tickers": ["NVDA", "AAPL", "C", "BAC", "MRK", "NKE", "ORCL", "DIS", "DPZ", "AMD", "SCHW", "GILD", "AMZN"], "title": "Volatility in the stock market during the third quarter gave institutional investors a chance to buy the dips. Taking a look at 13F filings from well-known institutional portfolios, we see that the big guns were busy adding new companies to their portfolios or expanding existing holdings. Buying occurred across a range of sectors. Vickers Stock Research, a subsidiary of Argus Research Group, analyzes insider trading and institutional stock ownership. Form 13-Fs, which institutions must file to report their holdings, are due 45 days after the end of calendar quarters and have come in for 3Q24. We review 13Fs of major institutional investors, including activists, to see what they are buying and to look for trends. Activist investing is now less about generating a short-term return and more about achieving long-term returns through an active management/investor partnerships. Based on data from Vickers, the following is a list of select purchases made in the third quarter by some high-profile money managers, including the Argus Research investment ratings."}, {"id": "3209_Analyst Report_1731436073000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2024-11-12T18:27:53Z", "reportTitle": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.", "targetPrice": 125.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500."}, {"id": "41803_Market Update_1731435173000", "headHtml": "Market Update: CB, CMG, MCK, MRK, VSH", "provider": "Argus Research", "reportDate": "2024-11-12T18:12:53Z", "reportTitle": "The major indices are lower at midday. The Russell 2000 is off 1%. The yield on the 10-year Treasury note is up 9 bps at 4.40%. Oil is flat at $68 per barrel. Bitcoin is down 1% but still over $86,000.", "tickers": ["MCK", "MRK", "VSH", "CMG", "CB"], "title": "The major indices are lower at midday. The Russell 2000 is off 1%. The yield on the 10-year Treasury note is up 9 bps at 4.40%. Oil is flat at $68 per barrel. Bitcoin is down 1% but still over $86,000."}, {"id": "3209_Analyst Report_1722597055000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2024-08-02T11:10:55Z", "reportTitle": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.", "targetPrice": 140.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500."}, {"id": "40795_Market Summary_1722596155000", "headHtml": "Market Digest: TEVA, HIG, LRCX, MAS, MRK, SBUX, WDC, META, HCA, IGT, RITM", "provider": "Argus Research", "reportDate": "2024-08-02T10:55:55Z", "reportTitle": "U.S. stocks sold off across the board in Thursday following soft economic data. The ISM manufacturing data hit an 8-month low. The weekly jobless claims rose more than expected. The S&P 500 fell 1.4%, the Dow dropped 1.2% and the Nasdaq lost 2.4%.", "tickers": ["META", "SBUX", "RITM", "IGT", "HCA", "HIG", "MRK", "WDC", "LRCX", "TEVA", "MAS"], "title": "U.S. stocks sold off across the board in Thursday following soft economic data. The ISM manufacturing data hit an 8-month low. The weekly jobless claims rose more than expected. The S&P 500 fell 1.4%, the Dow dropped 1.2% and the Nasdaq lost 2.4%."}, {"id": "40747_Stock Picks_1722253746000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2024-07-29T11:49:06Z", "reportTitle": "Artificial intelligence (AI) has become a pervasive technology in the Healthcare sector. Companies have been adopting AI in medical imaging, drug discovery, documentation, and administration. In medical imaging and diagnostics, AI is advancing rapidly in the detection of tumors, infections, and fractures. In drug discovery, vast data sets are being used to identify potential drugs to treat disease and predict their efficacy. AI also can improve trial design and create treatments for a wider range of people, including those with rare diseases. The technology also has helped to create more-efficient methods for documenting medical information with Automatic Speech Recognition (ASR). ASR enables voice-to-text technology and increases the productivity of medical staff by nearly 10%. For administrative tasks, AI has streamlined billing, scheduling, and fraud detection (a major issue that raises medical expenses for consumers). Here is a list of Argus BUY-rated Healthcare stocks that are leaders in the use of AI.", "tickers": ["SYK", "AZN", "MRK", "MDT", "MRNA", "ISRG", "UNH"], "title": "Artificial intelligence (AI) has become a pervasive technology in the Healthcare sector. Companies have been adopting AI in medical imaging, drug discovery, documentation, and administration. In medical imaging and diagnostics, AI is advancing rapidly in the detection of tumors, infections, and fractures. In drug discovery, vast data sets are being used to identify potential drugs to treat disease and predict their efficacy. AI also can improve trial design and create treatments for a wider range of people, including those with rare diseases. The technology also has helped to create more-efficient methods for documenting medical information with Automatic Speech Recognition (ASR). ASR enables voice-to-text technology and increases the productivity of medical staff by nearly 10%. For administrative tasks, AI has streamlined billing, scheduling, and fraud detection (a major issue that raises medical expenses for consumers). Here is a list of Argus BUY-rated Healthcare stocks that are leaders in the use of AI."}, {"id": "40660_Thematic Portfolio_1721401229000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2024-07-19T15:00:29Z", "reportTitle": "Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.", "tickers": ["CSCO", "VZ", "WRB", "JNJ", "MRK", "ABT", "GLW", "WM", "TRV", "CME", "SO", "CMI", "TJX", "KO", "OMC", "COP", "HON", "KR", "VRTX", "CL", "AEP", "VMC", "LMT", "ROP", "CMCSA", "MCK", "WEC", "XOM", "PG", "GPC", "HD", "MAR", "WMT"], "title": "Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods."}, {"id": "40660_Thematic Portfolio_1721400329000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2024-07-19T14:45:29Z", "reportTitle": "Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.", "tickers": ["CSCO", "VZ", "WRB", "JNJ", "MRK", "ABT", "GLW", "WM", "TRV", "CME", "SO", "CMI", "TJX", "KO", "OMC", "COP", "HON", "KR", "VRTX", "CL", "AEP", "VMC", "LMT", "ROP", "CMCSA", "MCK", "WEC", "XOM", "PG", "GPC", "HD", "MAR", "WMT"], "title": "Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods."}, {"id": "40327_Stock Picks_1718624987000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2024-06-17T11:49:47Z", "reportTitle": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.", "tickers": ["MDLZ", "CRWD", "MRK", "HPE"], "title": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus."}, {"id": "40310_Market Outlook_1718362886000", "headHtml": "Daily Spotlight: Argus Adjusts Sector Ratings", "provider": "Argus Research", "reportDate": "2024-06-14T11:01:26Z", "reportTitle": "We have reviewed our recommended sector allocations this month, and based on the analysis we have adjusted our current sector Over-Weight, Under-Weight, and Market-Weight recommendations. Our multi-factor model includes a performance-ranking system, which assigns points for monthly, quarterly, and YTD sector performance versus the benchmark S&P 500; current sector P/E versus five-year P/E, with points awarded for discount to S&P 500 current versus five-year P/E delta; two-year earnings growth, with points awarded for exceeding the benchmark average and for EPS acceleration; relative performance to the sector group average; sector conviction, meaning BUY rating percentage per sector versus total Argus BUY-rating percentage; and PEG ratio, with points awarded or subtracted based on sector PEG ratios below or above the group average. Our process yielded 42 total points, for an average sector score of 3.8. To earn an Over-Weight designation, sectors had to score five points or above; for Market-Weight, three or four points; and for Under-Weight, two points or below. Our current Over-Weight sectors are Healthcare, Communication Services, Financial, and Information Technology. Our current Market-Weight sectors are Consumer Discretionary, Energy (raised from Under-Weight), Industrials, Real Estate and Utilities. Our Under-Weight sectors are Materials and Consumer Staples. We suggest that advisors and investors leverage this consistent and comprehensive process to adjust sector weightings within their diversified equity portfolios, with a primary focus on the largest sectors.", "tickers": ["MRK"], "title": "We have reviewed our recommended sector allocations this month, and based on the analysis we have adjusted our current sector Over-Weight, Under-Weight, and Market-Weight recommendations. Our multi-factor model includes a performance-ranking system, which assigns points for monthly, quarterly, and YTD sector performance versus the benchmark S&P 500; current sector P/E versus five-year P/E, with points awarded for discount to S&P 500 current versus five-year P/E delta; two-year earnings growth, with points awarded for exceeding the benchmark average and for EPS acceleration; relative performance to the sector group average; sector conviction, meaning BUY rating percentage per sector versus total Argus BUY-rating percentage; and PEG ratio, with points awarded or subtracted based on sector PEG ratios below or above the group average. Our process yielded 42 total points, for an average sector score of 3.8. To earn an Over-Weight designation, sectors had to score five points or above; for Market-Weight, three or four points; and for Under-Weight, two points or below. Our current Over-Weight sectors are Healthcare, Communication Services, Financial, and Information Technology. Our current Market-Weight sectors are Consumer Discretionary, Energy (raised from Under-Weight), Industrials, Real Estate and Utilities. Our Under-Weight sectors are Materials and Consumer Staples. We suggest that advisors and investors leverage this consistent and comprehensive process to adjust sector weightings within their diversified equity portfolios, with a primary focus on the largest sectors."}, {"id": "40281_Portfolio Ideas_1718194289000", "headHtml": "May Stock Recovery as Economy Sends Mixed Signals", "provider": "Argus Research", "reportDate": "2024-06-12T12:11:29Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Crowdstrike Holdings Inc (CRWD); Mondelez International Inc. (MDLZ); Hewlett Packard Enterprise Co (HPE) and the Focus List deletions are CIENA Corp. (CIEN); General Mills, Inc. (GIS); ServiceNow Inc (NOW); Vertex Pharmaceuticals, Inc. (VRTX).", "tickers": ["CIEN", "GIS", "MDLZ", "CRWD", "MRK", "NOW", "VRTX", "HPE"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Crowdstrike Holdings Inc (CRWD); Mondelez International Inc. (MDLZ); Hewlett Packard Enterprise Co (HPE) and the Focus List deletions are CIENA Corp. (CIEN); General Mills, Inc. (GIS); ServiceNow Inc (NOW); Vertex Pharmaceuticals, Inc. (VRTX)."}, {"id": "40281_Portfolio Ideas_1718193389000", "headHtml": "May Stock Recovery as Economy Sends Mixed Signals", "provider": "Argus Research", "reportDate": "2024-06-12T11:56:29Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Crowdstrike Holdings Inc (CRWD); Mondelez International Inc. (MDLZ); Hewlett Packard Enterprise Co (HPE) and the Focus List deletions are CIENA Corp. (CIEN); General Mills, Inc. (GIS); ServiceNow Inc (NOW); Vertex Pharmaceuticals, Inc. (VRTX).", "tickers": ["CIEN", "GIS", "MDLZ", "CRWD", "MRK", "NOW", "VRTX", "HPE"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Crowdstrike Holdings Inc (CRWD); Mondelez International Inc. (MDLZ); Hewlett Packard Enterprise Co (HPE) and the Focus List deletions are CIENA Corp. (CIEN); General Mills, Inc. (GIS); ServiceNow Inc (NOW); Vertex Pharmaceuticals, Inc. (VRTX)."}, {"id": "40254_Stock Picks_1718022156000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2024-06-10T12:22:36Z", "reportTitle": "ESG (Environmental, Social, Governance) investing continues to grow. BlackRock CEO Lawrence Fink, who oversees approximately $9 trillion in assets, announced in January 2020 that his firm would be investing in companies that are making progress on sustainability. He doubled down in his January 2021 letter, calling on company managements to disclose their plans for making their businesses \"compatible with a net-zero economy\" by 2050. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol, and firearms. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes \"sustainable\" business practices across all industries that can have an \"impact\" on global issues such as climate, hunger, poverty, disease, shelter, and workers' rights. At Argus Research, we track ESG developments at specific companies as part of our Management analysis - one of the six points in our proprietary Six-Point Fundamental Approach. In addition to reviewing and measuring the ESG proclamations from the companies under coverage, we partner with an ESG research firm, the JUST Capital Foundation, and leverage its analysis and insights on the topic as well. JUST Capital's mission is to drive measurable corporate change to create a stakeholder-centric, inclusive form of capitalism that reflects the priorities of the American public. JUST utilizes a combination of data-driven research and strategic engagement in an attempt to shift norms and practices in corporate America and the financial markets. JUST ESG Custom Ratings rank stocks in the Russell 1000 on these criteria using a scale of 1-100. Drawing on the JUST Capital rankings, we have compiled focused lists of companies followed by Argus Research that are in position to have this type of \"sustainable impact\" on the environment, workplace, community, and marketplace. These firms have exemplary records not only in delivering on the bottom line, but also in improving the environment, contributing to community relations, and showing respect for their employees. We also have a Theme Model Portfolio based in part on the ESG criteria. To build the Argus U.S. ESG Model Portfolio, we applied financial concepts such as industry diversification, income generation, risk reduction, and growth at a reasonable price to our various lists. In addition, all stocks must be on the Argus BUY list. Here are the new stocks that have been added to the Argus U.S. ESG Model Portfolio.", "tickers": ["TFC", "WRK", "INTU", "MRK", "RSG", "GS", "AMZN", "GE", "DHR"], "title": "ESG (Environmental, Social, Governance) investing continues to grow. BlackRock CEO Lawrence Fink, who oversees approximately $9 trillion in assets, announced in January 2020 that his firm would be investing in companies that are making progress on sustainability. He doubled down in his January 2021 letter, calling on company managements to disclose their plans for making their businesses \"compatible with a net-zero economy\" by 2050. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol, and firearms. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes \"sustainable\" business practices across all industries that can have an \"impact\" on global issues such as climate, hunger, poverty, disease, shelter, and workers' rights. At Argus Research, we track ESG developments at specific companies as part of our Management analysis - one of the six points in our proprietary Six-Point Fundamental Approach. In addition to reviewing and measuring the ESG proclamations from the companies under coverage, we partner with an ESG research firm, the JUST Capital Foundation, and leverage its analysis and insights on the topic as well. JUST Capital's mission is to drive measurable corporate change to create a stakeholder-centric, inclusive form of capitalism that reflects the priorities of the American public. JUST utilizes a combination of data-driven research and strategic engagement in an attempt to shift norms and practices in corporate America and the financial markets. JUST ESG Custom Ratings rank stocks in the Russell 1000 on these criteria using a scale of 1-100. Drawing on the JUST Capital rankings, we have compiled focused lists of companies followed by Argus Research that are in position to have this type of \"sustainable impact\" on the environment, workplace, community, and marketplace. These firms have exemplary records not only in delivering on the bottom line, but also in improving the environment, contributing to community relations, and showing respect for their employees. We also have a Theme Model Portfolio based in part on the ESG criteria. To build the Argus U.S. ESG Model Portfolio, we applied financial concepts such as industry diversification, income generation, risk reduction, and growth at a reasonable price to our various lists. In addition, all stocks must be on the Argus BUY list. Here are the new stocks that have been added to the Argus U.S. ESG Model Portfolio."}, {"id": "40207_Market Summary_1717584882000", "headHtml": "Market Digest: MRVL, ADM, APD, MRK, NTAP", "provider": "Argus Research", "reportDate": "2024-06-05T10:54:42Z", "reportTitle": "To sum up the current stock market, we offer 'bend but don't break!' And yes, that is typical in a bull market. The S&P 500 (SPX) fell to 5,192 on May 31, about 10 points from its flat 50-day average and almost exactly at its 10-week exponential moving average (EMA). The index then blasted off, closing 86 points off that low. The SPX was back above its 21-day exponential average and the false breakout (generally bearish) on May 1 may be put to rest. ", "tickers": ["NTAP", "APD", "MRK", "ADM", "MRVL"], "title": "To sum up the current stock market, we offer 'bend but don't break!' And yes, that is typical in a bull market. The S&P 500 (SPX) fell to 5,192 on May 31, about 10 points from its flat 50-day average and almost exactly at its 10-week exponential moving average (EMA). The index then blasted off, closing 86 points off that low. The SPX was back above its 21-day exponential average and the false breakout (generally bearish) on May 1 may be put to rest. "}, {"id": "3209_Analyst Report_1717584882000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2024-06-05T10:54:42Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 140.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "40141_Thematic Portfolio_1716993465000", "headHtml": "The Argus ESG Model Portfolio", "provider": "Argus Research", "reportDate": "2024-05-29T14:37:45Z", "reportTitle": "Sustainable Impact Investing, or ESG investing, is gaining traction not only with Argus Research clients but also with the global investment community. BlackRock CEO Lawrence Fink, who oversees approximately $9 trillion in assets, announced in January 2020 that his firm would be investing in companies that are making progress on sustainability. He doubled down in his January 2021 letter, calling on company managements to disclose their plans for making their businesses \"compatible with a net-zero economy\" by 2050. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol, and firearms. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes \"sustainable\" business practices across all industries that can have an \"impact\" on global issues such as climate, hunger, poverty, disease, shelter, and workers' rights.", "tickers": ["TT", "GOOGL", "AAPL", "AVGO", "INTU", "JPM", "MRK", "DHR", "MSFT", "TFC", "WRK", "MA", "QCOM", "LRCX", "LLY", "SPGI", "TRV", "GE", "KLAC", "NVDA", "COP", "BSX", "RSG", "GS", "ECL", "TMUS", "CTAS", "ETN", "AMZN", "WMT"], "title": "Sustainable Impact Investing, or ESG investing, is gaining traction not only with Argus Research clients but also with the global investment community. BlackRock CEO Lawrence Fink, who oversees approximately $9 trillion in assets, announced in January 2020 that his firm would be investing in companies that are making progress on sustainability. He doubled down in his January 2021 letter, calling on company managements to disclose their plans for making their businesses \"compatible with a net-zero economy\" by 2050. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol, and firearms. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes \"sustainable\" business practices across all industries that can have an \"impact\" on global issues such as climate, hunger, poverty, disease, shelter, and workers' rights."}, {"id": "39427_Stock Picks_1710761642000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2024-03-18T11:34:02Z", "reportTitle": "We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.", "tickers": ["SYK", "BSX", "NVO", "JNJ", "MRK", "AMGN", "DHR", "IQV", "ABT", "MCK", "BDX", "TMO", "LLY", "ZTS", "REGN", "ISRG", "GSK", "SNY"], "title": "We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below."}, {"id": "3209_Analyst Report_1707306372000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2024-02-07T11:46:12Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 140.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "39039_Market Summary_1707305472000", "headHtml": "Market Digest: AJG, CAT, J, MDT, MRK, NUE, KKR, NOW, NXPI", "provider": "Argus Research", "reportDate": "2024-02-07T11:31:12Z", "reportTitle": "Early last year, the consensus belief had the economy headed toward a recession and the Federal Reserve needing to be aggressive with interest-rate cuts to prevent significant weakness in GDP. As 2023 progressed, the recession callers backed off as the economy kept its footing after the huge hike in the fed funds rate as well as the entire Treasury curve. And while inflation came down a lot faster than may thought, it did so without a concurrent weakening in the economy. ", "tickers": ["KKR", "NXPI", "CAT", "MRK", "NOW", "J", "MDT", "AJG", "NUE"], "title": "Early last year, the consensus belief had the economy headed toward a recession and the Federal Reserve needing to be aggressive with interest-rate cuts to prevent significant weakness in GDP. As 2023 progressed, the recession callers backed off as the economy kept its footing after the huge hike in the fed funds rate as well as the entire Treasury curve. And while inflation came down a lot faster than may thought, it did so without a concurrent weakening in the economy. "}, {"id": "39008_Top/Bottom Insider Activity_1707133375000", "headHtml": "Daily \u2013 Vickers Top Buyers & Sellers for 02/05/2024", "provider": "Argus Research", "reportDate": "2024-02-05T11:42:55Z", "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.", "tickers": ["BLK", "BMN", "SXTP", "MRK", "COLB", "MPB", "SIGI"], "title": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions."}, {"id": "38252_Top/Bottom Insider Activity_1699875676000", "headHtml": "Daily \u2013 Vickers Top Buyers & Sellers for 11/13/2023", "provider": "Argus Research", "reportDate": "2023-11-13T11:41:16Z", "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.", "tickers": ["BR", "B", "TYL", "MRK", "AMD", "FARO", "APH", "MPWR", "ALGN", "AURA"], "title": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions."}, {"id": "38244_Top/Bottom Insider Activity_1699618241000", "headHtml": "Daily \u2013 Vickers Top Buyers & Sellers for 11/10/2023", "provider": "Argus Research", "reportDate": "2023-11-10T12:10:41Z", "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.", "tickers": ["BR", "B", "TYL", "MRK", "AMD", "FARO", "APH", "MPWR", "ALGN", "AURA"], "title": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions."}, {"id": "38162_Market Summary_1698921146000", "headHtml": "Market Digest: AMD, DHR, ETR, MRK, NI, RJF, STX, OSTK, WRB, AGNC, NOW", "provider": "Argus Research", "reportDate": "2023-11-02T10:32:26Z", "reportTitle": "Stubborn Inflation, Sturdy Consumers: Our Monthly Survey of the Economy, Interest Rates, and Stocks", "tickers": ["ETR", "AGNC", "STX", "WRB", "MRK", "NOW", "AMD", "NI", "OSTK", "DHR", "RJF"], "title": "Stubborn Inflation, Sturdy Consumers: Our Monthly Survey of the Economy, Interest Rates, and Stocks"}, {"id": "3209_Analyst Report_1698921146000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2023-11-02T10:32:26Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 120.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "37930_Portfolio Ideas_1696960205000", "headHtml": "Fed, Rising Energy Costs Pressure Stocks", "provider": "Argus Research", "reportDate": "2023-10-10T17:50:05Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are MongoDB Inc (MDB); General Mills, Inc. (GIS); Unitedhealth Group Inc (UNH); TJX Companies, Inc. (TJX) and the Focus List deletions are Merck & Co Inc (MRK); J.M. Smucker Co. (SJM); Splunk Inc (SPLK); Ulta Beauty Inc (ULTA).", "tickers": ["GIS", "TJX", "ULTA", "MRK", "SJM", "MDB", "SPLK", "UNH"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are MongoDB Inc (MDB); General Mills, Inc. (GIS); Unitedhealth Group Inc (UNH); TJX Companies, Inc. (TJX) and the Focus List deletions are Merck & Co Inc (MRK); J.M. Smucker Co. (SJM); Splunk Inc (SPLK); Ulta Beauty Inc (ULTA)."}, {"id": "37622_Stock Picks_1694431424000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2023-09-11T11:23:44Z", "reportTitle": "We see some possible gems right now in the Healthcare sector. Overall, we have a sector rating of Market-Weight, but this category is broad and has underperformed the S&P 500 year-to-date. The Healthcare ETF (XLV) is down 1.6% year-to-date compared to a gain of 19% for the S&P 500. We see opportunity to pick up some consistently steady companies, with big brands, and solid financials. These companies are science-focused, enhance lives, and are innovators. Some have recently raised guidance, communicating management's confidence. In our list this week, we look across several subsectors within the industry and pull out some leaders that we like.", "tickers": ["MCK", "CTLT", "MRK", "LLY", "ISRG", "BIIB"], "title": "We see some possible gems right now in the Healthcare sector. Overall, we have a sector rating of Market-Weight, but this category is broad and has underperformed the S&P 500 year-to-date. The Healthcare ETF (XLV) is down 1.6% year-to-date compared to a gain of 19% for the S&P 500. We see opportunity to pick up some consistently steady companies, with big brands, and solid financials. These companies are science-focused, enhance lives, and are innovators. Some have recently raised guidance, communicating management's confidence. In our list this week, we look across several subsectors within the industry and pull out some leaders that we like."}, {"id": "3209_Analyst Report_1693567711000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2023-09-01T11:28:31Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 125.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "37545_Market Summary_1693566811000", "headHtml": "Market Digest: BTI, MRK", "provider": "Argus Research", "reportDate": "2023-09-01T11:13:31Z", "reportTitle": "Stocks were mixed on Thursday. The Commerce Department said that the Personal Consumption Expenditures Index excluding the cost of food and energy, or so-called 'core' PCE, rose 4.2% over the prior year in July, in line with economist expectations and up from 4.1% in June. Personal consumption expenditures rose 0.8% versus 0.6% the month prior. Personal income grew 0.2% in the month, while disposable income was flat. On the employment front, first-time claims for state unemployment benefits fell by 4,000 to a seasonally adjusted 235,000 for the week ended August 26. Continuing claims rose by 28,000 to 1.725 million. The Dow fell 0.5%, the S&P 0.2%, and the Nasdaq rose 0.1%. Crude oil traded near $84 per barrel, while gold fell $6 to $1967 per ounce.", "tickers": ["BTI", "MRK"], "title": "Stocks were mixed on Thursday. The Commerce Department said that the Personal Consumption Expenditures Index excluding the cost of food and energy, or so-called 'core' PCE, rose 4.2% over the prior year in July, in line with economist expectations and up from 4.1% in June. Personal consumption expenditures rose 0.8% versus 0.6% the month prior. Personal income grew 0.2% in the month, while disposable income was flat. On the employment front, first-time claims for state unemployment benefits fell by 4,000 to a seasonally adjusted 235,000 for the week ended August 26. Continuing claims rose by 28,000 to 1.725 million. The Dow fell 0.5%, the S&P 0.2%, and the Nasdaq rose 0.1%. Crude oil traded near $84 per barrel, while gold fell $6 to $1967 per ounce."}, {"id": "37068_Stock Picks_1689595240000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2023-07-17T12:00:40Z", "reportTitle": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.", "tickers": ["TSLA", "MRK", "ADBE", "WMT"], "title": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus."}, {"id": "37024_Portfolio Ideas_1689161977000", "headHtml": "AI Drives the First-Half 2023 Stock Market", "provider": "Argus Research", "reportDate": "2023-07-12T11:39:37Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Tesla Inc (TSLA); Walmart Inc (WMT); Merck & Co Inc (MRK); Adobe Inc (ADBE) and the Focus List deletions are DraftKings Inc. (DKNG); Dell Technologies Inc (DELL); Thermo Fisher Scientific Inc. (TMO); Coca-Cola Co (KO).", "tickers": ["DKNG", "TSLA", "KO", "MRK", "TMO", "ADBE", "DELL", "WMT"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Tesla Inc (TSLA); Walmart Inc (WMT); Merck & Co Inc (MRK); Adobe Inc (ADBE) and the Focus List deletions are DraftKings Inc. (DKNG); Dell Technologies Inc (DELL); Thermo Fisher Scientific Inc. (TMO); Coca-Cola Co (KO)."}, {"id": "36827_Technical Analysis_1687346645000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2023-06-21T11:24:05Z", "reportTitle": "The Nasdaq and Nasdaq 100 (NDX) are taking a breather from strong rallies in May and June, and the S&P 500 is seemingly on a break from its so-far nice June rally. But while the indices have run into important resistance, we are seeing good signs of market breadth in large-market-cap stock indices.", "tickers": ["MRK", "ISRG"], "title": "The Nasdaq and Nasdaq 100 (NDX) are taking a breather from strong rallies in May and June, and the S&P 500 is seemingly on a break from its so-far nice June rally. But while the indices have run into important resistance, we are seeing good signs of market breadth in large-market-cap stock indices."}, {"id": "3209_Analyst Report_1686050400000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2023-06-06T11:20:00Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 125.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "36682_Market Summary_1686049500000", "headHtml": "Market Digest: KSS, MRK, OSK, QSR", "provider": "Argus Research", "reportDate": "2023-06-06T11:05:00Z", "reportTitle": "In our previous commentary on insider sentiment, we noted five weeks of bullish sentiment based on data from Vickers Stock Research. We also noted a slowing in the bullish mood; not a move to neutral or bearish, but a slowing in the growth of bullish sentiment. Among the data, insider sentiment from companies that list on the Nasdaq remained atop the leader board.", "tickers": ["QSR", "OSK", "MRK", "KSS"], "title": "In our previous commentary on insider sentiment, we noted five weeks of bullish sentiment based on data from Vickers Stock Research. We also noted a slowing in the bullish mood; not a move to neutral or bearish, but a slowing in the growth of bullish sentiment. Among the data, insider sentiment from companies that list on the Nasdaq remained atop the leader board."}, {"id": "36394_Technical Analysis_1683545646000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2023-05-08T11:34:06Z", "reportTitle": "There are many first-quarter EPS reports still to come. But, so far, the stock market seems to be taking results in stride. In addition to more EPS reports, we have some Fed speakers as well as CPI and PPI releases this week. The big three indices (S&P 500, Nasdaq, and Nasdaq 100) are all sitting at the top of their recent ranges -- and, as hard as it has been for them to break through, they are certainly set up to do so.", "tickers": ["MRK", "PWR"], "title": "There are many first-quarter EPS reports still to come. But, so far, the stock market seems to be taking results in stride. In addition to more EPS reports, we have some Fed speakers as well as CPI and PPI releases this week. The big three indices (S&P 500, Nasdaq, and Nasdaq 100) are all sitting at the top of their recent ranges -- and, as hard as it has been for them to break through, they are certainly set up to do so."}, {"id": "36173_Technical Analysis_1681469618000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2023-04-14T10:53:38Z", "reportTitle": "While we maintain our long-term neutral technical assessment, there are some positive developments from certain momentum indicators. These are weekly or monthly indicators and can take a long time to change from bullish to bearish and back again. As well, they don't whipsaws the way shorter-term measures can, which is a good thing. The one fault, if it is a fault, is that long-term momentum measures will never get you in at the bottom of an intermediate- to longer-term trend and will never get you out near the top of a rising trend. But this doesn't really concern us, as the most consistent money is made during the heart of a trend and not by trying to time tops and bottoms, which is a treacherous and very difficult undertaking.", "tickers": ["MSFT", "MRK"], "title": "While we maintain our long-term neutral technical assessment, there are some positive developments from certain momentum indicators. These are weekly or monthly indicators and can take a long time to change from bullish to bearish and back again. As well, they don't whipsaws the way shorter-term measures can, which is a good thing. The one fault, if it is a fault, is that long-term momentum measures will never get you in at the bottom of an intermediate- to longer-term trend and will never get you out near the top of a rising trend. But this doesn't really concern us, as the most consistent money is made during the heart of a trend and not by trying to time tops and bottoms, which is a treacherous and very difficult undertaking."}, {"id": "35873_Market Summary_1678879938000", "headHtml": "Market Digest: LVS, MRK, NSC, GNRC, DOCU", "provider": "Argus Research", "reportDate": "2023-03-15T11:32:18Z", "reportTitle": "Stocks held up on March 13 after some ugly early action that saw the S&P 500 (SPX) down about 1.3%. The index rallied almost 100 points by late morning before selling off over the balance of the day. It was a great session for day traders, but created more agita for the rest of us. The morning low coincided with chart support in the 3,780-3,810 region from the late-December low. On March 14, gains were solid and broad-based.", "tickers": ["MRK", "LVS", "GNRC", "DOCU", "NSC"], "title": "Stocks held up on March 13 after some ugly early action that saw the S&P 500 (SPX) down about 1.3%. The index rallied almost 100 points by late morning before selling off over the balance of the day. It was a great session for day traders, but created more agita for the rest of us. The morning low coincided with chart support in the 3,780-3,810 region from the late-December low. On March 14, gains were solid and broad-based."}, {"id": "3209_Analyst Report_1678879938000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2023-03-15T11:32:18Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 115.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "35820_Portfolio Ideas_1678365786000", "headHtml": "Recession on Hold", "provider": "Argus Research", "reportDate": "2023-03-09T12:43:06Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Raymond James Financial, Inc. (RJF); Sonoco Products Co. (SON); Arista Networks Inc (ANET); Lilly(Eli) & Co (LLY) and the Focus List deletions are Merck & Co Inc (MRK); Huntington Bancshares, Inc. (HBAN); Quanta Services, Inc. (PWR); HubSpot Inc (HUBS).", "tickers": ["ANET", "SON", "HBAN", "MRK", "LLY", "PWR", "HUBS", "RJF"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Raymond James Financial, Inc. (RJF); Sonoco Products Co. (SON); Arista Networks Inc (ANET); Lilly(Eli) & Co (LLY) and the Focus List deletions are Merck & Co Inc (MRK); Huntington Bancshares, Inc. (HBAN); Quanta Services, Inc. (PWR); HubSpot Inc (HUBS)."}, {"id": "35788_Technical Analysis_1678190669000", "headHtml": "Technical Assessment: Bullish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2023-03-07T12:04:29Z", "reportTitle": "In Monday's commentary, we talked about one of the things missing from this potential new bull market -- namely, a lockout rally. Persistent strength is a common theme after \"the\" low is in. In 1982, the 13-week rate-of-change (ROC) after the bottom was 37% and the S&P 500 (SPX) rose in 10 of those 13 weeks. Off the secondary low in early 1991, the 14W ROC was 22% with 10 of 14 weeks positive. In 1998, the 13W gain was 30% and the \"500\" rose in 10 of 13 weeks. After the technology meltdown, the 13W bounce off the 2003 low was 20%, with 10 of 13 weeks on the upside. After the financial crises, we witnessed a 38% rally in 2009, with the index rising in 11 of 13 weeks. Following the 2011 secondary low, the 16W rate-of-change was 22%, with advances in 13 of 16 weeks.", "tickers": ["MRK", "FTV"], "title": "In Monday's commentary, we talked about one of the things missing from this potential new bull market -- namely, a lockout rally. Persistent strength is a common theme after \"the\" low is in. In 1982, the 13-week rate-of-change (ROC) after the bottom was 37% and the S&P 500 (SPX) rose in 10 of those 13 weeks. Off the secondary low in early 1991, the 14W ROC was 22% with 10 of 14 weeks positive. In 1998, the 13W gain was 30% and the \"500\" rose in 10 of 13 weeks. After the technology meltdown, the 13W bounce off the 2003 low was 20%, with 10 of 13 weeks on the upside. After the financial crises, we witnessed a 38% rally in 2009, with the index rising in 11 of 13 weeks. Following the 2011 secondary low, the 16W rate-of-change was 22%, with advances in 13 of 16 weeks."}, {"id": "35687_Market Outlook_1677240159000", "headHtml": "Daily Spotlight: Fed's Favorite Inflation Indicator Out Today", "provider": "Argus Research", "reportDate": "2023-02-24T12:02:39Z", "reportTitle": "The Federal Reserve's favorite inflation indicator, PCE Price Index, will be released today. This index differs from the better-known Consumer Price Index in that its composition is changed more frequently and is thus quicker to reflect the impact of real-time pricing fluctuations. In the most-recent report, from December, PCE inflation was reported at 5.0% (the latest CPI report, from January, had inflation at 6.4%). At Argus, we forecast a rate of 5.0% for the January PCE Price Index. Core PCE, which removes food and energy prices, was 4.4% in the latest month. We expect Core PCE to remain steady at 4.4% this month. Inflation appears to have peaked during the summer and is continuing to decline, though the rate of decline may slow in the months ahead. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 4.2% rate year-over-year, down from 4.7% a month ago and 8.7% six months ago. Focusing on core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate and the 10-year TIPs Break-even Interest Rate), our reading is 3.7%, down from 3.9% last month. We note some movement among our components. Producer Prices appear to be cooling, with substantial declines in PPI Final Demand and Intermediate Prices for Unprocessed Goods. The rate of wage increases also is stable/slowing.  But the Sticky Price Index is drifting higher. Investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 2.7% and the five-year forward expectation rate at 2.3%.", "tickers": ["MRK"], "title": "The Federal Reserve's favorite inflation indicator, PCE Price Index, will be released today. This index differs from the better-known Consumer Price Index in that its composition is changed more frequently and is thus quicker to reflect the impact of real-time pricing fluctuations. In the most-recent report, from December, PCE inflation was reported at 5.0% (the latest CPI report, from January, had inflation at 6.4%). At Argus, we forecast a rate of 5.0% for the January PCE Price Index. Core PCE, which removes food and energy prices, was 4.4% in the latest month. We expect Core PCE to remain steady at 4.4% this month. Inflation appears to have peaked during the summer and is continuing to decline, though the rate of decline may slow in the months ahead. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 4.2% rate year-over-year, down from 4.7% a month ago and 8.7% six months ago. Focusing on core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate and the 10-year TIPs Break-even Interest Rate), our reading is 3.7%, down from 3.9% last month. We note some movement among our components. Producer Prices appear to be cooling, with substantial declines in PPI Final Demand and Intermediate Prices for Unprocessed Goods. The rate of wage increases also is stable/slowing.  But the Sticky Price Index is drifting higher. Investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 2.7% and the five-year forward expectation rate at 2.3%."}, {"id": "35405_Thematic Portfolio_1674748218000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2023-01-26T15:50:18Z", "reportTitle": "Rapidly rising inflation 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower last year. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those fixed-income returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.5% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate.", "tickers": ["CSCO", "CTVA", "VZ", "JNJ", "MRK", "TXN", "ADP", "PFE", "DHR", "ABT", "UNP", "WM", "TRV", "KO", "OMC", "BCE", "HON", "CL", "AEP", "AVB", "HSY", "MCD", "EXC", "LMT", "MCK", "APD", "XOM", "PG", "ENB", "PEP", "GPC", "AJG", "WMT"], "title": "Rapidly rising inflation 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower last year. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those fixed-income returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.5% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate."}, {"id": "35120_Market Outlook_1671797269000", "headHtml": "Daily Spotlight: Important Inflation News Out Today", "provider": "Argus Research", "reportDate": "2022-12-23T12:07:49Z", "reportTitle": "The Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most recent report, from October, PCE inflation was reported at 6.0% (the latest CPI report, from November, had inflation at 7.1%). At Argus, we forecast a rate of 5.7% for the November PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.0% in the latest month. We expect the Core PCE to tick lower to 4.8% this month. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 4.7% rate year-over-year, down from 5.2% last month and from 8.7% six months ago. Focusing on core inflation, our reading is 4.0%, down slightly from our 4.2% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing down. Looking ahead, investors are expecting that the Federal Reserve's series of rate hikes will ultimately tame inflation, with the three-year forward expectation rate now down to 3.0% and the five-year forward expectation rate at 2.1%.", "tickers": ["MRK"], "title": "The Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most recent report, from October, PCE inflation was reported at 6.0% (the latest CPI report, from November, had inflation at 7.1%). At Argus, we forecast a rate of 5.7% for the November PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.0% in the latest month. We expect the Core PCE to tick lower to 4.8% this month. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 4.7% rate year-over-year, down from 5.2% last month and from 8.7% six months ago. Focusing on core inflation, our reading is 4.0%, down slightly from our 4.2% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing down. Looking ahead, investors are expecting that the Federal Reserve's series of rate hikes will ultimately tame inflation, with the three-year forward expectation rate now down to 3.0% and the five-year forward expectation rate at 2.1%."}, {"id": "3209_Analyst Report_1668514689000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2022-11-15T12:18:09Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 110.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "34725_Market Summary_1668513789000", "headHtml": "Market Digest: EAT, MRK, PRU, PM, PSX, LTHM", "provider": "Argus Research", "reportDate": "2022-11-15T12:03:09Z", "reportTitle": "As earnings season began in mid-October, insider sentiment was solidly positive and we wrote the following: 'Insiders just won't give in to the dire mood on Wall Street.' Over the next three weeks, insider-sentiment gauges from Vickers Stock Research turned in a cautious direction based on light transaction volume (with insiders broadly prohibited from trading during earnings season). Now, with earnings season drawing to a close and insiders starting to trade again, the rubber meets the road. ", "tickers": ["PRU", "PSX", "MRK", "EAT", "PM", "LTHM"], "title": "As earnings season began in mid-October, insider sentiment was solidly positive and we wrote the following: 'Insiders just won't give in to the dire mood on Wall Street.' Over the next three weeks, insider-sentiment gauges from Vickers Stock Research turned in a cautious direction based on light transaction volume (with insiders broadly prohibited from trading during earnings season). Now, with earnings season drawing to a close and insiders starting to trade again, the rubber meets the road. "}, {"id": "34626_Technical Analysis_1667559944000", "headHtml": "Technical Assessment: Bullish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2022-11-04T11:05:44Z", "reportTitle": "From the view of a chartist with an economic background, the Fed often might do more harm than good - especially when it is late to tighten and late to ease. One could argue that if the Fed simply watched and quickly followed market rates, goals could be achieved more quickly. Often, it seems, the central bank lets the economy get out of control on the upside and then economic contractions become far worse than they should.", "tickers": ["KMI", "MRK"], "title": "From the view of a chartist with an economic background, the Fed often might do more harm than good - especially when it is late to tighten and late to ease. One could argue that if the Fed simply watched and quickly followed market rates, goals could be achieved more quickly. Often, it seems, the central bank lets the economy get out of control on the upside and then economic contractions become far worse than they should."}, {"id": "34598_Top/Bottom Insider Activity_1667385077000", "headHtml": "Daily \u2013 Vickers Top Buyers & Sellers for 11/02/2022", "provider": "Argus Research", "reportDate": "2022-11-02T10:31:17Z", "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.", "tickers": ["TBBK", "JUPW", "EHC", "BHVN", "DCOM", "HCA", "MRK", "SMR", "SCHW", "GS"], "title": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions."}, {"id": "34562_Market Outlook_1666955139000", "headHtml": "Daily Spotlight: Important Inflation News Out Today", "provider": "Argus Research", "reportDate": "2022-10-28T11:05:39Z", "reportTitle": "The Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Price Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations.  In August, PCE inflation was reported at 6.2% (the latest CPI report, from September, was 8.2%). At Argus, we forecast a rate of 6.0% for the September PCE Price Index. Core PCE, which removes volatile food and energy prices, was 4.9% in August. We expect a tick lower to 4.8% in September. Overall, inflation appears to have peaked during the summer and may be starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 6.8% rate year-over-year, down from 7.1% last month and from 8.7% three months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the Five-Year Forward Inflation Expectation Rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.2%, essentially in line with a 4.1% reading last month. We note some movement among our components. Producer Prices appear to be cooling, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing down. Looking farther out, investors are expecting that the Federal Reserve's series of rate hikes ultimately will corral inflation, with the Five-Year Forward Expectation Rate now down at 2.3%.", "tickers": ["MRK"], "title": "The Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Price Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations.  In August, PCE inflation was reported at 6.2% (the latest CPI report, from September, was 8.2%). At Argus, we forecast a rate of 6.0% for the September PCE Price Index. Core PCE, which removes volatile food and energy prices, was 4.9% in August. We expect a tick lower to 4.8% in September. Overall, inflation appears to have peaked during the summer and may be starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 6.8% rate year-over-year, down from 7.1% last month and from 8.7% three months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the Five-Year Forward Inflation Expectation Rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.2%, essentially in line with a 4.1% reading last month. We note some movement among our components. Producer Prices appear to be cooling, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing down. Looking farther out, investors are expecting that the Federal Reserve's series of rate hikes ultimately will corral inflation, with the Five-Year Forward Expectation Rate now down at 2.3%."}, {"id": "34436_Stock Picks_1666006325000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2022-10-17T11:32:05Z", "reportTitle": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Director of Research Kelleher typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.", "tickers": ["TGT", "FOXA", "MRK", "AJG"], "title": "Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Director of Research Kelleher typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus."}, {"id": "34423_Portfolio Ideas_1665763719000", "headHtml": "Recession Fears Rise Amid Mixed Data", "provider": "Argus Research", "reportDate": "2022-10-14T16:08:39Z", "reportTitle": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Fox Corporation (FOXA); Arthur J. Gallagher & Co. (AJG); Target Corp (TGT) and the Focus List deletions are Alphabet Inc (GOOGL); Laboratory Corp. Of America Hl (LH); SVB Financial Group (SIVB); TJX Companies, Inc. (TJX).", "tickers": ["TGT", "GOOGL", "FOXA", "TJX", "SIVB", "MRK", "LH", "AJG"], "title": "The Portfolio Selector features the Argus Focus List, a group of 30 \"best idea\" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Merck & Co Inc (MRK); Fox Corporation (FOXA); Arthur J. Gallagher & Co. (AJG); Target Corp (TGT) and the Focus List deletions are Alphabet Inc (GOOGL); Laboratory Corp. Of America Hl (LH); SVB Financial Group (SIVB); TJX Companies, Inc. (TJX)."}, {"id": "34371_Technical Analysis_1665485854000", "headHtml": "Technical Assessment: Bullish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2022-10-11T10:57:34Z", "reportTitle": "This year is turning into one of the worst for the S&P 500. At Monday's close, the year-to-date (YTD) return excluding dividends was an abysmal -24.2%. Over the past 30 years, this loss was exceeded only in 2008, when the \"500\" collapsed 38.5% during the financial crisis. The index is just a tick worse than 2002, when it declined 23.4%. Even after all these losses this year, we still do not know whether we are even in a recession yet -- and corporate earnings estimates for 2022 and 2023 have not been cut very much.", "tickers": ["CTVA", "MRK"], "title": "This year is turning into one of the worst for the S&P 500. At Monday's close, the year-to-date (YTD) return excluding dividends was an abysmal -24.2%. Over the past 30 years, this loss was exceeded only in 2008, when the \"500\" collapsed 38.5% during the financial crisis. The index is just a tick worse than 2002, when it declined 23.4%. Even after all these losses this year, we still do not know whether we are even in a recession yet -- and corporate earnings estimates for 2022 and 2023 have not been cut very much."}, {"id": "34361_Stock Picks_1665401832000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2022-10-10T11:37:12Z", "reportTitle": "Healthcare is a sector that includes many categories and investing disciplines. It is innovative, can be either growth or value, and can involve start-ups or mature companies. A healthcare company can be built around one product that is leveraged in broad and creative ways, or a company with depth, breadth and products that have many touchpoints. Many of the companies are truly science-based, some with managers who are stronger as scientists than as executives running a company; others have scientists focus on science while practiced managers mind the books. The Healthcare sector accounts for 15% of the S&P 500, with an overall market cap of $1.4 trillion dollars. Subsectors include Biotechnology, Healthcare Distributors, Healthcare Equipment, Healthcare Supplies, Life Sciences Tools and Services, Managed Healthcare, and Pharmaceuticals. We think investors should Over-Weight the sector and consider allocating about 15% of their diversified portfolios to stocks in the sector. Healthcare is slightly outperforming the S&P 500 thus far in 2022, with a loss of 14% compared to the 25% loss for the S&P 500. The following are some Argus BUY-rated Healthcare companies. The stocks were selected using the Argus screening tool and the following criteria: BUY-rated; large-cap (greater than $8 billion market capitalization); a Financial Strength rating of Medium-High or High; and paying a dividend. We feel these companies currently are best in class for the sector. Some are also part of our model portfolios (Growth & Income, Equity Income, Growth, and Institutional).", "tickers": ["DGX", "BDX", "JNJ", "MRK", "ZTS", "RHHBY", "PFE", "UNH"], "title": "Healthcare is a sector that includes many categories and investing disciplines. It is innovative, can be either growth or value, and can involve start-ups or mature companies. A healthcare company can be built around one product that is leveraged in broad and creative ways, or a company with depth, breadth and products that have many touchpoints. Many of the companies are truly science-based, some with managers who are stronger as scientists than as executives running a company; others have scientists focus on science while practiced managers mind the books. The Healthcare sector accounts for 15% of the S&P 500, with an overall market cap of $1.4 trillion dollars. Subsectors include Biotechnology, Healthcare Distributors, Healthcare Equipment, Healthcare Supplies, Life Sciences Tools and Services, Managed Healthcare, and Pharmaceuticals. We think investors should Over-Weight the sector and consider allocating about 15% of their diversified portfolios to stocks in the sector. Healthcare is slightly outperforming the S&P 500 thus far in 2022, with a loss of 14% compared to the 25% loss for the S&P 500. The following are some Argus BUY-rated Healthcare companies. The stocks were selected using the Argus screening tool and the following criteria: BUY-rated; large-cap (greater than $8 billion market capitalization); a Financial Strength rating of Medium-High or High; and paying a dividend. We feel these companies currently are best in class for the sector. Some are also part of our model portfolios (Growth & Income, Equity Income, Growth, and Institutional)."}, {"id": "34156_Stock Picks_1663587379000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2022-09-19T11:36:19Z", "reportTitle": "The broad market selloff on September 13 still feels raw, and the Federal Reserve has left no doubt that it will fight inflation vigorously for as long as it takes. Stocks, and likely many portfolios, are feeling some pain. In volatile times like these, when selling is widespread, a classic investing strategy is to focus on \u201cbest in class\u201d stocks. These are the strongest and most-stable stocks in each sector -- and by looking across sectors, diversification can also be achieved. To get our list this week, we ran multiple screens. We started with the Argus Min-Vol theme model portfolio. As the name suggests, that portfolio includes companies that likely can best withstand market fluctuations. We then shortlisted the group by also screening for financial strength and dividend yield. And, finally, we picked one stock from each of the 11 S&P sectors. The following stocks are our Best in Class for Safety recommendations for September 2022, and all of them currently carry an Argus BUY rating.", "tickers": ["LMT", "CSCO", "KO", "VZ", "APD", "MRK", "ENB", "TRV", "AEP", "AVB", "MCD"], "title": "The broad market selloff on September 13 still feels raw, and the Federal Reserve has left no doubt that it will fight inflation vigorously for as long as it takes. Stocks, and likely many portfolios, are feeling some pain. In volatile times like these, when selling is widespread, a classic investing strategy is to focus on \u201cbest in class\u201d stocks. These are the strongest and most-stable stocks in each sector -- and by looking across sectors, diversification can also be achieved. To get our list this week, we ran multiple screens. We started with the Argus Min-Vol theme model portfolio. As the name suggests, that portfolio includes companies that likely can best withstand market fluctuations. We then shortlisted the group by also screening for financial strength and dividend yield. And, finally, we picked one stock from each of the 11 S&P sectors. The following stocks are our Best in Class for Safety recommendations for September 2022, and all of them currently carry an Argus BUY rating."}, {"id": "3209_Analyst Report_1660131062000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2022-08-10T11:31:02Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 100.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "33760_Market Summary_1660130162000", "headHtml": "Market Digest: CP, CHKP, ETD, EXPE, FLEX, MET, MRK, NFG, JCI, GNRC, TWLO", "provider": "Argus Research", "reportDate": "2022-08-10T11:16:02Z", "reportTitle": "The S&P 500 ran into key resistance recently at the 4,175 region and, so far, the pause looks like it could be a bull flag. The index has come a long way, so we will give the bulls the benefit of the doubt in the short term. Of course, a break of the flag to the upside would bring the next piece of resistance into view at 4,225, which is a 50% retracement of the bear market.", "tickers": ["JCI", "TWLO", "ETD", "CHKP", "MRK", "EXPE", "FLEX", "GNRC", "CP", "MET", "NFG"], "title": "The S&P 500 ran into key resistance recently at the 4,175 region and, so far, the pause looks like it could be a bull flag. The index has come a long way, so we will give the bulls the benefit of the doubt in the short term. Of course, a break of the flag to the upside would bring the next piece of resistance into view at 4,225, which is a 50% retracement of the bear market."}, {"id": "33645_Thematic Portfolio_1659015021000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2022-07-28T13:30:21Z", "reportTitle": "Rapidly rising inflation in 2022 has knocked the stock market into a bear market. While growth strategies have suffered the most, value strategies also have declined. Even year-to-date bond prices are lower. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.0% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.", "tickers": ["CSCO", "VZ", "JNJ", "MRK", "TXN", "RHHBY", "ADP", "PFE", "DHR", "ABT", "UNP", "WM", "UL", "TRV", "AEE", "KO", "OMC", "BCE", "HON", "CL", "AEP", "AVB", "DEO", "HSY", "MCD", "LMT", "APD", "XOM", "PG", "ENB", "PEP", "GPC", "WMT"], "title": "Rapidly rising inflation in 2022 has knocked the stock market into a bear market. While growth strategies have suffered the most, value strategies also have declined. Even year-to-date bond prices are lower. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.0% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods."}, {"id": "33434_Technical Analysis_1657177229000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2022-07-07T07:00:29Z", "reportTitle": "The U.S. dollar (USD), which bottomed at 90 in late 2020 and May 2021, has been in a nice uptrend ever since. The greenback hit 107 on Wednesday, its highest level since 12/2002. So much for protecting your purchasing power with gold, silver, or Bitcoin, which have been slaughtered. Not too long ago, there was much talk about the USD heading a lot lower and losing its status as the global currency.", "tickers": ["MRK", "LH"], "title": "The U.S. dollar (USD), which bottomed at 90 in late 2020 and May 2021, has been in a nice uptrend ever since. The greenback hit 107 on Wednesday, its highest level since 12/2002. So much for protecting your purchasing power with gold, silver, or Bitcoin, which have been slaughtered. Not too long ago, there was much talk about the USD heading a lot lower and losing its status as the global currency."}, {"id": "33335_Stock Picks_1656315775000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2022-06-27T07:42:55Z", "reportTitle": "Stocks have struggled in 2Q 2022, with the S&P 500 on its way to a double-digit drop for the period.  Absent the rally in recent days, the decline would be closer to 20%. Growth stocks have again been the weakest performers, as sectors such as Technology, Communication Services, and Consumer Discretionary all have lagged the major market indices. The leading sectors were value-oriented, including Energy, Consumer Staples, Basic Materials, and Utilities. The average stock in the Argus Universe of Coverage has declined 13.1% thus far during the quarter, and the median stock declined 12.5%. The average BUY-rated stock dropped 12.6%, while the average HOLD-rated stock fell 14.4%. Will investors continue to favor value in 2022? Will high inflation drive continued outperformance in Energy and Basic Materials? Given interest rates that remain historically low, we expect growth stocks to resume outperformance over time, and think 2022 may be a \"one-in-five year\" that value leads. Investors seeking value are encouraged to focus on dividends and look for yields in the 3%-4% range.  Concerning sectors, our current Over-Weights are Energy, Financial, Healthcare, Industrials, and Basic Materials. Here are the top-10 and bottom-five performers from the Argus Universe in 2Q.", "tickers": ["ACC", "DINO", "MNST", "PTON", "MRK", "BBBY", "VRTX", "K", "SNAP", "TUP", "UTHR", "T", "SWX", "LLY", "LYFT"], "title": "Stocks have struggled in 2Q 2022, with the S&P 500 on its way to a double-digit drop for the period.  Absent the rally in recent days, the decline would be closer to 20%. Growth stocks have again been the weakest performers, as sectors such as Technology, Communication Services, and Consumer Discretionary all have lagged the major market indices. The leading sectors were value-oriented, including Energy, Consumer Staples, Basic Materials, and Utilities. The average stock in the Argus Universe of Coverage has declined 13.1% thus far during the quarter, and the median stock declined 12.5%. The average BUY-rated stock dropped 12.6%, while the average HOLD-rated stock fell 14.4%. Will investors continue to favor value in 2022? Will high inflation drive continued outperformance in Energy and Basic Materials? Given interest rates that remain historically low, we expect growth stocks to resume outperformance over time, and think 2022 may be a \"one-in-five year\" that value leads. Investors seeking value are encouraged to focus on dividends and look for yields in the 3%-4% range.  Concerning sectors, our current Over-Weights are Energy, Financial, Healthcare, Industrials, and Basic Materials. Here are the top-10 and bottom-five performers from the Argus Universe in 2Q."}, {"id": "32987_Technical Analysis_1653030308000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2022-05-20T07:05:08Z", "reportTitle": "Following April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the \"500\" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.", "tickers": ["ALB", "MRK"], "title": "Following April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the \"500\" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%."}, {"id": "3209_Analyst Report_1652878955000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2022-05-18T13:02:35Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 110.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "32963_Market Update_1652878055000", "headHtml": "Market Update: CENT, COP, HD, MRK, NOK", "provider": "Argus Research", "reportDate": "2022-05-18T12:47:35Z", "reportTitle": "Stocks fell sharply on Wednesday morning amid more earnings reports from major retailers. Target shares plunged 24% after the company reported much weaker than expected 1Q earnings and warned of further pressure from rising fuel and freight costs. Lowe's shares also fell, despite above-consensus earnings, as investors focused on the company's disappointing comps sales. The Dow fell 1.9%, the S&P 2.1%, and the Nasdaq 2.3%. Crude oil fell 1% to $111.50 per barrel, while gold fell $7 to $1812 per ounce.", "tickers": ["COP", "CENT", "MRK", "NOK", "HD"], "title": "Stocks fell sharply on Wednesday morning amid more earnings reports from major retailers. Target shares plunged 24% after the company reported much weaker than expected 1Q earnings and warned of further pressure from rising fuel and freight costs. Lowe's shares also fell, despite above-consensus earnings, as investors focused on the company's disappointing comps sales. The Dow fell 1.9%, the S&P 2.1%, and the Nasdaq 2.3%. Crude oil fell 1% to $111.50 per barrel, while gold fell $7 to $1812 per ounce."}, {"id": "32872_Technical Analysis_1652166737000", "headHtml": "Technical Assessment: Bearish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2022-05-10T07:12:17Z", "reportTitle": "Monday was yet another washout day, as the major indices lost 3% to 4% -- with the heaviest losses in Energy, Real Estate, Consumer Discretionary, Technology, Basic Materials, Healthcare, and Communication Services. More of the same.", "tickers": ["MRK", "WMT"], "title": "Monday was yet another washout day, as the major indices lost 3% to 4% -- with the heaviest losses in Energy, Real Estate, Consumer Discretionary, Technology, Basic Materials, Healthcare, and Communication Services. More of the same."}, {"id": "32668_Stock Picks_1650267146000", "headHtml": "Weekly Stock List", "provider": "Argus Research", "reportDate": "2022-04-18T07:32:26Z", "reportTitle": "Our rating on the Healthcare sector is Over-Weight. Consumers are now more willing to spend on lifestyle enhancements along with necessary spending on life-saving treatments. In addition, the survival of the Affordable Care Act has kept the ranks of insured U.S. citizens above the historical average, further increasing consumer spending on healthcare services and products. Meanwhile, companies with experience in diagnostic testing, vaccines, and antiviral medicines, as well as suppliers of protective equipment and other hospital products, should benefit from efforts to contain the pandemic. The sector accounts for 13.7% of the S&P 500, and includes companies in the pharmaceuticals, medical devices, healthcare services, and insurance industries. The sector is outperforming the market thus far in 2022, with a gain of 1.3% through early April, while the S&P 500 has declined 6%. The following are examples of how we use our analysts' Healthcare sector ideas in our Focus List and Model Portfolios.  All stocks are rated BUY at Argus.", "tickers": ["CVS", "SYK", "CTLT", "JNJ", "MRK", "VRTX", "ABBV", "DHR", "IQV", "TECH", "ABT", "MCK", "BDX", "TMO", "LLY", "ZTS", "MDT", "LH", "MRNA", "ISRG", "GSK"], "title": "Our rating on the Healthcare sector is Over-Weight. Consumers are now more willing to spend on lifestyle enhancements along with necessary spending on life-saving treatments. In addition, the survival of the Affordable Care Act has kept the ranks of insured U.S. citizens above the historical average, further increasing consumer spending on healthcare services and products. Meanwhile, companies with experience in diagnostic testing, vaccines, and antiviral medicines, as well as suppliers of protective equipment and other hospital products, should benefit from efforts to contain the pandemic. The sector accounts for 13.7% of the S&P 500, and includes companies in the pharmaceuticals, medical devices, healthcare services, and insurance industries. The sector is outperforming the market thus far in 2022, with a gain of 1.3% through early April, while the S&P 500 has declined 6%. The following are examples of how we use our analysts' Healthcare sector ideas in our Focus List and Model Portfolios.  All stocks are rated BUY at Argus."}, {"id": "3209_Analyst Report_1645017761000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2022-02-16T13:22:41Z", "reportTitle": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 110.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "32172_Market Update_1645016861000", "headHtml": "Market Update: TPR, K, MDU, MRK, TMUS, LIN, UBER", "provider": "Argus Research", "reportDate": "2022-02-16T13:07:41Z", "reportTitle": "Stocks fell on Wednesday morning, giving up some of Tuesday's gains, led by declines in the Technology and Communication Services sectors. Retail sales data was stronger than expected. The Commerce Department said that U.S. retail sales rose 3.8% in January, above the consensus estimate of 2.0%, after a 2.5% decline in in December. The Dow fell 0.6%, the S&P 0.6%, and the Nasdaq 1.0%. Crude oil traded near $95 per barrel, while gold rose $7 to $1863 per ounce.", "tickers": ["LIN", "TMUS", "MRK", "TPR", "K", "UBER", "MDU"], "title": "Stocks fell on Wednesday morning, giving up some of Tuesday's gains, led by declines in the Technology and Communication Services sectors. Retail sales data was stronger than expected. The Commerce Department said that U.S. retail sales rose 3.8% in January, above the consensus estimate of 2.0%, after a 2.5% decline in in December. The Dow fell 0.6%, the S&P 0.6%, and the Nasdaq 1.0%. Crude oil traded near $95 per barrel, while gold rose $7 to $1863 per ounce."}, {"id": "31993_Thematic Portfolio_1643287499000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2022-01-27T12:44:59Z", "reportTitle": "The onset of the coronavirus in 2020 knocked stocks into a bear market. Though equities recovered, the U.S. economy is about to slow down and COVID-19 cases are rising again as virus variants spread. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels.  Daily prices can swing wildly, as they did three times in 2021 when stocks dropped 4%-5% in a matter of a few days. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those returns are from eras when the 10-year Treasury bond yield was not sub-2.0%. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.", "tickers": ["CSCO", "VZ", "JNJ", "MRK", "TXN", "RHHBY", "PFE", "DHR", "MSFT", "ABT", "WM", "UL", "UPS", "AEE", "KO", "ICE", "ACN", "AEP", "DEO", "MCD", "LMT", "ROP", "CMCSA", "APD", "PG", "ENB", "PEP", "CHD", "ODFL", "WMT"], "title": "The onset of the coronavirus in 2020 knocked stocks into a bear market. Though equities recovered, the U.S. economy is about to slow down and COVID-19 cases are rising again as virus variants spread. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels.  Daily prices can swing wildly, as they did three times in 2021 when stocks dropped 4%-5% in a matter of a few days. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those returns are from eras when the 10-year Treasury bond yield was not sub-2.0%. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods."}, {"id": "31276_Market Summary_1635752351000", "headHtml": "Market Digest: BA, BMY, CME, GD, MCO, MRK, WDC, FB, DLR, LIN, CARR", "provider": "Argus Research", "reportDate": "2021-11-01T07:39:11Z", "reportTitle": "The stock market moved higher last week during the busiest days of earnings season. Tech stocks far outperformed blue chips, though a portion of the outperformance was attributable to Tesla, as its stock is included in the S&P 500 and Nasdaq Composite, but not the DJIA. During Friday's session, the Dow Jones Industrial Average increased 89 points, or 0.25%. The S&P 500 was up 0.19%, and the Nasdaq Composite was up 0.33%. For the week, the DJIA was up 143 points, or 0.40%, the S&P 500 was up 1.33%, and the Nasdaq Composite was up 2.70%. For the YTD, the DJIA is up 17.03%, the S&P 500 is up 22.61%, and the Nasdaq Composite is up 20.25%.", "tickers": ["LIN", "CARR", "META", "MRK", "WDC", "MCO", "CME", "DLR", "GD", "BA", "BMY"], "title": "The stock market moved higher last week during the busiest days of earnings season. Tech stocks far outperformed blue chips, though a portion of the outperformance was attributable to Tesla, as its stock is included in the S&P 500 and Nasdaq Composite, but not the DJIA. During Friday's session, the Dow Jones Industrial Average increased 89 points, or 0.25%. The S&P 500 was up 0.19%, and the Nasdaq Composite was up 0.33%. For the week, the DJIA was up 143 points, or 0.40%, the S&P 500 was up 1.33%, and the Nasdaq Composite was up 2.70%. For the YTD, the DJIA is up 17.03%, the S&P 500 is up 22.61%, and the Nasdaq Composite is up 20.25%."}, {"id": "3209_Analyst Report_1635752351000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2021-11-01T07:39:11Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 110.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "3209_Analyst Report_1628771697000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2021-08-12T12:34:57Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "investmentRating": "Neutral", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "30625_Market Update_1628770797000", "headHtml": "Market Update: AIG, APD, MRK, NLOK, TSN", "provider": "Argus Research", "reportDate": "2021-08-12T12:19:57Z", "reportTitle": "Stocks fell on Thursday morning following new weekly employment data and a producer price report that again pointed to high inflation. The Labor Department said that first-time claims for state unemployment benefits fell to 375,000 for the week ended August 7, down from 387,000 a week earlier and in line with the consensus forecast. On the earnings front, eBay shares fell after the company posted mixed 2Q results and offered disappointing third-quarter sales guidance. The Dow fell 0.3%, the S&P 0.3%, and the Nasdaq 0.4%. Crude oil rose to $69 per barrel, while gold traded near $1749 per ounce.", "tickers": ["APD", "MRK", "NLOK", "TSN", "AIG"], "title": "Stocks fell on Thursday morning following new weekly employment data and a producer price report that again pointed to high inflation. The Labor Department said that first-time claims for state unemployment benefits fell to 375,000 for the week ended August 7, down from 387,000 a week earlier and in line with the consensus forecast. On the earnings front, eBay shares fell after the company posted mixed 2Q results and offered disappointing third-quarter sales guidance. The Dow fell 0.3%, the S&P 0.3%, and the Nasdaq 0.4%. Crude oil rose to $69 per barrel, while gold traded near $1749 per ounce."}, {"id": "30483_Thematic Portfolio_1627381274000", "headHtml": "The Argus Min Vol Model Portfolio", "provider": "Argus Research", "reportDate": "2021-07-27T10:21:14Z", "reportTitle": "The onset of the coronavirus in 2020 knocked the stock market into a bear market. Though stocks have recovered, the U.S. economy is about to slow down and COVID-19 cases are rising again as virus variants spread. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels.  Daily prices can swing wildly, as they did during two consecutive days in mid-July when the Dow Jones Industrial Average plummeted more than 1,000 points. Yet investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes. Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate and can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.", "tickers": ["CSCO", "VZ", "JNJ", "MRK", "TXN", "AMGN", "PFE", "DHR", "MSFT", "WM", "UL", "UPS", "MKC", "AMT", "CL", "ICE", "ACN", "MMM", "MCD", "NEE", "LMT", "CMCSA", "WEC", "APD", "PG", "ENB", "PEP", "CHD", "ODFL", "WMT"], "title": "The onset of the coronavirus in 2020 knocked the stock market into a bear market. Though stocks have recovered, the U.S. economy is about to slow down and COVID-19 cases are rising again as virus variants spread. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels.  Daily prices can swing wildly, as they did during two consecutive days in mid-July when the Dow Jones Industrial Average plummeted more than 1,000 points. Yet investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes. Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate and can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods."}, {"id": "3209_Analyst Report_1621495141000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2021-05-20T07:19:01Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "investmentRating": "Neutral", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "29931_Market Summary_1621494241000", "headHtml": "Market Digest: ADI, LH, MRK, WEN, WYNN, DISCA, VNT", "provider": "Argus Research", "reportDate": "2021-05-20T07:04:01Z", "reportTitle": "Inflation: Out of the Bag?", "tickers": ["WEN", "ADI", "MRK", "WYNN", "DISCA", "LH", "VNT"], "title": "Inflation: Out of the Bag?"}, {"id": "3209_Analyst Report_1616741493000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2021-03-26T06:51:33Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 88.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "29473_Market Summary_1616740593000", "headHtml": "Market Digest: DRI, MRK, SPH", "provider": "Argus Research", "reportDate": "2021-03-26T06:36:33Z", "reportTitle": "Stocks erased morning losses to close higher on Thursday. The energy sector was the worst performer and tech shares also lagged. On the employment front, the Labor Department said that first-time claims for state unemployment benefits fell to 684,000 for the week ended March 20, down from 781,000 a week earlier and below the Bloomberg consensus forecast of 730,000. This was the lowest number since before the pandemic. The GDP increased at an annual rate of 4.3% according to the third estimate, up from the second estimate of 4.1%. Fed Chair Jerome Powell reiterated that the Fed is committed to targeting 2% average inflation rate. The Dow rose 0.6%, the S&P 0.5%, and the Nasdaq 0.1%. Crude oil settled at $58 per barrel, while gold fell nearly $8 to $1725 per ounce.", "tickers": ["MRK", "DRI", "SPH"], "title": "Stocks erased morning losses to close higher on Thursday. The energy sector was the worst performer and tech shares also lagged. On the employment front, the Labor Department said that first-time claims for state unemployment benefits fell to 684,000 for the week ended March 20, down from 781,000 a week earlier and below the Bloomberg consensus forecast of 730,000. This was the lowest number since before the pandemic. The GDP increased at an annual rate of 4.3% according to the third estimate, up from the second estimate of 4.1%. Fed Chair Jerome Powell reiterated that the Fed is committed to targeting 2% average inflation rate. The Dow rose 0.6%, the S&P 0.5%, and the Nasdaq 0.1%. Crude oil settled at $58 per barrel, while gold fell nearly $8 to $1725 per ounce."}, {"id": "28728_Thematic Portfolio_1608633108000", "headHtml": "The Argus High-Yield Model Portfolio", "provider": "Argus Research", "reportDate": "2020-12-22T10:31:48Z", "reportTitle": "Growth stocks may be outperforming value, again, in 2020. But in an environment of historically low interest rates (and with the coronavirus and economic shutdown seemingly poised to keep them low for a long time), many investors are still searching for high levels of income, which can often be found in value stocks. Progress on COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past quarter. The current yield on the iShares Russell 1000 Value Index ETF is 2.5%, compared to the 1.0% current yield on the iShares Russell 1000 Growth Index ETF.  This is not unimportant, as the current yield on the 10-year Treasury bond is 0.95%.", "tickers": ["AVGO", "CVX", "VZ", "AGNC", "CFG", "MRK", "K", "PPL", "NFG", "PFE", "TFC", "PRU", "T", "IBM", "STX", "PNW", "VLO", "NLY", "SO", "MO", "USB", "ABBV", "PKG", "LMT", "PSX", "EIX", "REG", "ENB", "GPC", "MET"], "title": "Growth stocks may be outperforming value, again, in 2020. But in an environment of historically low interest rates (and with the coronavirus and economic shutdown seemingly poised to keep them low for a long time), many investors are still searching for high levels of income, which can often be found in value stocks. Progress on COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past quarter. The current yield on the iShares Russell 1000 Value Index ETF is 2.5%, compared to the 1.0% current yield on the iShares Russell 1000 Growth Index ETF.  This is not unimportant, as the current yield on the 10-year Treasury bond is 0.95%."}, {"id": "3209_Analyst Report_1604993075000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-11-10T07:24:35Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "28389_Market Summary_1604993075000", "headHtml": "Market Digest: CAKE, HFC, MRK, PH, BRK/B, AWK, CTVA", "provider": "Argus Research", "reportDate": "2020-11-10T07:24:35Z", "reportTitle": "As earnings season moves towards completion, the volume of insider transactions is returning to normal, lending increased significance to the proprietary sentiment indicators from Vickers Stock Research. For three consecutive weeks during the heart of earnings, insiders turned bearish in a manner that exceeded the norm for that time on the calendar. During the bearish turn, the DJIA moved from 28,586 (close on 10/12/20) down to 26,501 (close on 11/2/20). Insiders then became bullish -- and one week later, the DJIA was back up to 28,323 (close on 11/6/20).  So what gives this week?", "tickers": ["CTVA", "HFC", "AWK", "CAKE", "MRK", "BRK-B", "PH"], "title": "As earnings season moves towards completion, the volume of insider transactions is returning to normal, lending increased significance to the proprietary sentiment indicators from Vickers Stock Research. For three consecutive weeks during the heart of earnings, insiders turned bearish in a manner that exceeded the norm for that time on the calendar. During the bearish turn, the DJIA moved from 28,586 (close on 10/12/20) down to 26,501 (close on 11/2/20). Insiders then became bullish -- and one week later, the DJIA was back up to 28,323 (close on 11/6/20).  So what gives this week?"}, {"id": "28389_Market Summary_1604992175000", "headHtml": "Market Digest: CAKE, HFC, MRK, PH, BRK/B, AWK, CTVA", "provider": "Argus Research", "reportDate": "2020-11-10T07:09:35Z", "reportTitle": "As earnings season moves towards completion, the volume of insider transactions is returning to normal, lending increased significance to the proprietary sentiment indicators from Vickers Stock Research. For three consecutive weeks during the heart of earnings, insiders turned bearish in a manner that exceeded the norm for that time on the calendar. During the bearish turn, the DJIA moved from 28,586 (close on 10/12/20) down to 26,501 (close on 11/2/20). Insiders then became bullish -- and one week later, the DJIA was back up to 28,323 (close on 11/6/20).  So what gives this week?", "tickers": ["CTVA", "HFC", "AWK", "CAKE", "MRK", "BRK-B", "PH"], "title": "As earnings season moves towards completion, the volume of insider transactions is returning to normal, lending increased significance to the proprietary sentiment indicators from Vickers Stock Research. For three consecutive weeks during the heart of earnings, insiders turned bearish in a manner that exceeded the norm for that time on the calendar. During the bearish turn, the DJIA moved from 28,586 (close on 10/12/20) down to 26,501 (close on 11/2/20). Insiders then became bullish -- and one week later, the DJIA was back up to 28,323 (close on 11/6/20).  So what gives this week?"}, {"id": "27678_Technical Analysis_1597390049000", "headHtml": "Technical Assessment: Bullish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2020-08-14T07:27:29Z", "reportTitle": "The S&P 500 has teased us this week, coming oh-so-close to the record closing high from February 19. Maybe today? While the stock market continues to defy gravity and logic, seemingly because of the impact on sentiment of massive stimulus (aka. liquidity), we have another sentiment indicator that has moved to a potentially precarious level.", "tickers": ["MRK", "WYNN"], "title": "The S&P 500 has teased us this week, coming oh-so-close to the record closing high from February 19. Maybe today? While the stock market continues to defy gravity and logic, seemingly because of the impact on sentiment of massive stimulus (aka. liquidity), we have another sentiment indicator that has moved to a potentially precarious level."}, {"id": "27678_Technical Analysis_1597363200000", "headHtml": "Technical Assessment: Bullish in the Intermediate-Term", "provider": "Argus Research", "reportDate": "2020-08-14T00:00:00Z", "reportTitle": "The S&P 500 has teased us this week, coming oh-so-close to the record closing high from February 19. Maybe today? While the stock market continues to defy gravity and logic, seemingly because of the impact on sentiment of massive stimulus (aka. liquidity), we have another sentiment indicator that has moved to a potentially precarious level.", "tickers": ["MRK", "WYNN"], "title": "The S&P 500 has teased us this week, coming oh-so-close to the record closing high from February 19. Maybe today? While the stock market continues to defy gravity and logic, seemingly because of the impact on sentiment of massive stimulus (aka. liquidity), we have another sentiment indicator that has moved to a potentially precarious level."}, {"id": "3209_Analyst Report_1597237012000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-08-12T12:56:52Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "27663_Market Update_1597236112000", "headHtml": "Market Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVA", "provider": "Argus Research", "reportDate": "2020-08-12T12:41:52Z", "reportTitle": "Stocks rose on Wednesday morning, rebounding from a late-day selloff on Tuesday despite the continued fiscal stimulus stalemate in Washington. The Labor Department reported that consumer prices rose 0.6% in July, unchanged from the prior month but above the Reuters consensus forecast of 0.3% growth. Prices also rose 1.0% from the prior year, above the consensus of 0.8%. Moderna shares rose on news that the company had won a $1.5 billion vaccine supply contract with the U.S. government. The Dow rose 1.0%, the S&P 1.3%, and the Nasdaq 2.0%. Crude oil traded near $42 per barrel, while gold rose $3 to $1949 per ounce.", "tickers": ["GOLD", "MO", "CTVA", "FBHS", "MRK", "ZTS", "CLS", "BKNG"], "title": "Stocks rose on Wednesday morning, rebounding from a late-day selloff on Tuesday despite the continued fiscal stimulus stalemate in Washington. The Labor Department reported that consumer prices rose 0.6% in July, unchanged from the prior month but above the Reuters consensus forecast of 0.3% growth. Prices also rose 1.0% from the prior year, above the consensus of 0.8%. Moderna shares rose on news that the company had won a $1.5 billion vaccine supply contract with the U.S. government. The Dow rose 1.0%, the S&P 1.3%, and the Nasdaq 2.0%. Crude oil traded near $42 per barrel, while gold rose $3 to $1949 per ounce."}, {"id": "27663_Market Update_1597190400000", "headHtml": "Market Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVA", "provider": "Argus Research", "reportDate": "2020-08-12T00:00:00Z", "reportTitle": "Stocks rose on Wednesday morning, rebounding from a late-day selloff on Tuesday despite the continued fiscal stimulus stalemate in Washington. The Labor Department reported that consumer prices rose 0.6% in July, unchanged from the prior month but above the Reuters consensus forecast of 0.3% growth. Prices also rose 1.0% from the prior year, above the consensus of 0.8%. Moderna shares rose on news that the company had won a $1.5 billion vaccine supply contract with the U.S. government. The Dow rose 1.0%, the S&P 1.3%, and the Nasdaq 2.0%. Crude oil traded near $42 per barrel, while gold rose $3 to $1949 per ounce.", "tickers": ["GOLD", "MO", "CTVA", "FBHS", "MRK", "ZTS", "CLS", "BKNG"], "title": "Stocks rose on Wednesday morning, rebounding from a late-day selloff on Tuesday despite the continued fiscal stimulus stalemate in Washington. The Labor Department reported that consumer prices rose 0.6% in July, unchanged from the prior month but above the Reuters consensus forecast of 0.3% growth. Prices also rose 1.0% from the prior year, above the consensus of 0.8%. Moderna shares rose on news that the company had won a $1.5 billion vaccine supply contract with the U.S. government. The Dow rose 1.0%, the S&P 1.3%, and the Nasdaq 2.0%. Crude oil traded near $42 per barrel, while gold rose $3 to $1949 per ounce."}, {"id": "3209_Analyst Report_1597190400000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-08-12T00:00:00Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "3209_Analyst Report_1588167656000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-04-29T13:40:56Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "26812_Market Update_1588166756000", "headHtml": "Market Update: HSY, IVZ, MA, MRK, SPGI, GIS, HCA, UPS", "provider": "Argus Research", "reportDate": "2020-04-29T13:25:56Z", "reportTitle": "Stocks rose on Wednesday morning as positive news about Gilead's potential coronavirus treatment outweighed a weak 1Q GDP report. The Commerce Department said that the U.S. economy contracted at a 4.8% annualized rate in 1Q20, the sharpest contraction since 4Q08. The Reuters consensus forecast had called for a decline of 4.0%. The Dow rose 2.1%, the S&P 2.4%, and the Nasdaq 3.0%. Crude oil rose $4 to $16.40 per barrel, while gold fell $9 to $1713 per ounce.", "tickers": ["GIS", "MA", "HCA", "MRK", "SPGI", "UPS", "IVZ", "HSY"], "title": "Stocks rose on Wednesday morning as positive news about Gilead's potential coronavirus treatment outweighed a weak 1Q GDP report. The Commerce Department said that the U.S. economy contracted at a 4.8% annualized rate in 1Q20, the sharpest contraction since 4Q08. The Reuters consensus forecast had called for a decline of 4.0%. The Dow rose 2.1%, the S&P 2.4%, and the Nasdaq 3.0%. Crude oil rose $4 to $16.40 per barrel, while gold fell $9 to $1713 per ounce."}, {"id": "3209_Analyst Report_1588118400000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-04-29T00:00:00Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "26812_Market Update_1588118400000", "headHtml": "Market Update: HSY, IVZ, MA, MRK, SPGI, GIS, HCA, UPS", "provider": "Argus Research", "reportDate": "2020-04-29T00:00:00Z", "reportTitle": "Stocks rose on Wednesday morning as positive news about Gilead's potential coronavirus treatment outweighed a weak 1Q GDP report. The Commerce Department said that the U.S. economy contracted at a 4.8% annualized rate in 1Q20, the sharpest contraction since 4Q08. The Reuters consensus forecast had called for a decline of 4.0%. The Dow rose 2.1%, the S&P 2.4%, and the Nasdaq 3.0%. Crude oil rose $4 to $16.40 per barrel, while gold fell $9 to $1713 per ounce.", "tickers": ["GIS", "MA", "HCA", "MRK", "SPGI", "UPS", "IVZ", "HSY"], "title": "Stocks rose on Wednesday morning as positive news about Gilead's potential coronavirus treatment outweighed a weak 1Q GDP report. The Commerce Department said that the U.S. economy contracted at a 4.8% annualized rate in 1Q20, the sharpest contraction since 4Q08. The Reuters consensus forecast had called for a decline of 4.0%. The Dow rose 2.1%, the S&P 2.4%, and the Nasdaq 3.0%. Crude oil rose $4 to $16.40 per barrel, while gold fell $9 to $1713 per ounce."}, {"id": "26624_Market Outlook_1586244367000", "headHtml": "Daily Spotlight: We Favor Large-Cap and U.S. Segments", "provider": "Argus Research", "reportDate": "2020-04-07T07:26:07Z", "reportTitle": "Bonds continued to extend their early performance lead in 2020, as coronavirus fears have driven investors out of riskier assets such as stocks and have increased demand for more-conservative, fixed-income securities. Despite the onset of the 2020 bear market, we favor stocks over bonds for long-term investors, U.S. stocks over international, growth stocks over value, and large-caps over small. Drilling deeper into equities, we look for large-cap companies with strong balance sheets and experienced management teams to be the leaders during an eventual recovery. Our recommended exposure to small- and mid-caps is now 10% of equity allocation, below the benchmark weighting. Internationally, U.S. stocks have outperformed global stocks over the trailing one- and five-year periods. We expect this to continue over the long term, given volatile global economic and currency conditions. That said, international stocks offer favorable near-term valuations, and we target 20% of equity exposure to the group. In terms of growth and value, growth (led by Tech) continues to outperform value, led by Energy. As there is no change expected in this dynamic over the next few quarters, we favor growth.", "tickers": ["MRK"], "title": "Bonds continued to extend their early performance lead in 2020, as coronavirus fears have driven investors out of riskier assets such as stocks and have increased demand for more-conservative, fixed-income securities. Despite the onset of the 2020 bear market, we favor stocks over bonds for long-term investors, U.S. stocks over international, growth stocks over value, and large-caps over small. Drilling deeper into equities, we look for large-cap companies with strong balance sheets and experienced management teams to be the leaders during an eventual recovery. Our recommended exposure to small- and mid-caps is now 10% of equity allocation, below the benchmark weighting. Internationally, U.S. stocks have outperformed global stocks over the trailing one- and five-year periods. We expect this to continue over the long term, given volatile global economic and currency conditions. That said, international stocks offer favorable near-term valuations, and we target 20% of equity exposure to the group. In terms of growth and value, growth (led by Tech) continues to outperform value, led by Energy. As there is no change expected in this dynamic over the next few quarters, we favor growth."}, {"id": "26624_Market Outlook_1586217600000", "headHtml": "Daily Spotlight: We Favor Large-Cap and U.S. Segments", "provider": "Argus Research", "reportDate": "2020-04-07T00:00:00Z", "reportTitle": "Bonds continued to extend their early performance lead in 2020, as coronavirus fears have driven investors out of riskier assets such as stocks and have increased demand for more-conservative, fixed-income securities. Despite the onset of the 2020 bear market, we favor stocks over bonds for long-term investors, U.S. stocks over international, growth stocks over value, and large-caps over small. Drilling deeper into equities, we look for large-cap companies with strong balance sheets and experienced management teams to be the leaders during an eventual recovery. Our recommended exposure to small- and mid-caps is now 10% of equity allocation, below the benchmark weighting. Internationally, U.S. stocks have outperformed global stocks over the trailing one- and five-year periods. We expect this to continue over the long term, given volatile global economic and currency conditions. That said, international stocks offer favorable near-term valuations, and we target 20% of equity exposure to the group. In terms of growth and value, growth (led by Tech) continues to outperform value, led by Energy. As there is no change expected in this dynamic over the next few quarters, we favor growth.", "tickers": ["MRK"], "title": "Bonds continued to extend their early performance lead in 2020, as coronavirus fears have driven investors out of riskier assets such as stocks and have increased demand for more-conservative, fixed-income securities. Despite the onset of the 2020 bear market, we favor stocks over bonds for long-term investors, U.S. stocks over international, growth stocks over value, and large-caps over small. Drilling deeper into equities, we look for large-cap companies with strong balance sheets and experienced management teams to be the leaders during an eventual recovery. Our recommended exposure to small- and mid-caps is now 10% of equity allocation, below the benchmark weighting. Internationally, U.S. stocks have outperformed global stocks over the trailing one- and five-year periods. We expect this to continue over the long term, given volatile global economic and currency conditions. That said, international stocks offer favorable near-term valuations, and we target 20% of equity exposure to the group. In terms of growth and value, growth (led by Tech) continues to outperform value, led by Energy. As there is no change expected in this dynamic over the next few quarters, we favor growth."}, {"id": "3209_Analyst Report_1585033925000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-03-24T07:12:05Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "26506_Market Summary_1585033025000", "headHtml": "Market Digest: LGND, SYY, TSLA, MRK, MCHP, QCOM, UN", "provider": "Argus Research", "reportDate": "2020-03-24T06:57:05Z", "reportTitle": "Stock prices continue to fall. Corporate executives, directors and beneficial owners continue to fall over themselves in a mad rush to acquire shares that we can only assume they view as significantly oversold. A mere month ago, life was 'normal' for most of us. Today it is not normal at all, yet insiders are acting as if this opportunity for investors is one that simply cannot be ignored.", "tickers": ["LGND", "SYY", "TSLA", "QCOM", "MRK", "UN", "MCHP"], "title": "Stock prices continue to fall. Corporate executives, directors and beneficial owners continue to fall over themselves in a mad rush to acquire shares that we can only assume they view as significantly oversold. A mere month ago, life was 'normal' for most of us. Today it is not normal at all, yet insiders are acting as if this opportunity for investors is one that simply cannot be ignored."}, {"id": "3209_Analyst Report_1585008000000", "headHtml": "Analyst Report: Merck & Co Inc", "provider": "Argus Research", "reportDate": "2020-03-24T00:00:00Z", "reportTitle": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.", "targetPrice": 95.0, "investmentRating": "Bullish", "tickers": ["MRK"], "title": "Merck & Co. is a leading worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500."}, {"id": "26506_Market Summary_1585008000000", "headHtml": "Market Digest: LGND, SYY, TSLA, MRK, MCHP, QCOM, UN", "provider": "Argus Research", "reportDate": "2020-03-24T00:00:00Z", "reportTitle": "Stock prices continue to fall. Corporate executives, directors and beneficial owners continue to fall over themselves in a mad rush to acquire shares that we can only assume they view as significantly oversold. A mere month ago, life was 'normal' for most of us. Today it is not normal at all, yet insiders are acting as if this opportunity for investors is one that simply cannot be ignored.", "tickers": ["LGND", "SYY", "TSLA", "QCOM", "MRK", "UN", "MCHP"], "title": "Stock prices continue to fall. Corporate executives, directors and beneficial owners continue to fall over themselves in a mad rush to acquire shares that we can only assume they view as significantly oversold. A mere month ago, life was 'normal' for most of us. Today it is not normal at all, yet insiders are acting as if this opportunity for investors is one that simply cannot be ignored."}], "sigDevs": [{"headline": "Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23", "date": "2025-03-27"}], "secReports": [{"id": "0001628280-25-007732_310158", "type": "Periodic Financial Reports", "title": "10-K : Periodic Financial Reports", "description": "Annual report pursuant to Section 13 and 15(d)", "filingDate": 1740441600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828025007732/thumbnail.png", "formType": "10-K"}, {"id": "0001104659-25-008863_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1738627200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465925008863/thumbnail.png", "formType": "8-K"}, {"id": "0001104659-24-122027_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1732233600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924122027/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-24-045689_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1730851200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024045689/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-24-112841_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1730332800000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924112841/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-24-034715_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1722816000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024034715/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-24-083722_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1722297600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924083722/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-24-025800_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1717027200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024025800/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-24-020283_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1714694400000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024020283/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-24-051517_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1714003200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924051517/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-24-015812_310158", "type": "Annual Report to Shareholders", "title": "ARS : Annual Report to Shareholders", "description": "Annual report to security holders", "filingDate": 1712793600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024015812/thumbnail.png", "formType": "ARS"}, {"id": "0001193125-24-093221_310158", "type": "Proxy Statements", "title": "DEFA14A : Proxy Statements", "description": "Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms", "filingDate": 1712793600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312524093221/thumbnail.png", "formType": "DEFA14A"}, {"id": "0001193125-24-093204_310158", "type": "Proxy Statements", "title": "DEF 14A : Proxy Statements", "description": "Definitive proxy statements", "filingDate": 1712793600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312524093204/thumbnail.png", "formType": "DEF 14A"}, {"id": "0001193125-24-093194_310158", "type": "Periodic Financial Reports", "title": "10-K/A : Periodic Financial Reports", "description": "Annual report pursuant to Section 13 and 15(d)", "filingDate": 1712793600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312524093194/thumbnail.png", "formType": "10-K/A"}, {"id": "0001193125-24-071348_310158", "type": "Offering Registrations", "title": "S-3ASR : Offering Registrations", "description": "Automatic shelf registration statement of securities of well-known seasoned issuers", "filingDate": 1710806400000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312524071348/thumbnail.png", "formType": "S-3ASR"}, {"id": "0001193125-24-071343_310158", "type": "Offering Registrations", "title": "S-3ASR : Offering Registrations", "description": "Automatic shelf registration statement of securities of well-known seasoned issuers", "filingDate": 1710806400000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312524071343/thumbnail.png", "formType": "S-3ASR"}, {"id": "0001193125-24-064741_64978", "type": "Tender Offer/Acquisition Reports", "title": "SC 13D/A : Tender Offer/Acquisition Reports", "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities", "filingDate": 1710115200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001708493/000119312524064741/thumbnail.png", "formType": "SC 13D/A"}, {"id": "0001628280-24-006850_310158", "type": "Periodic Financial Reports", "title": "10-K : Periodic Financial Reports", "description": "Annual report pursuant to Section 13 and 15(d)", "filingDate": 1708905600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828024006850/thumbnail.png", "formType": "10-K"}, {"id": "0001104659-24-025524_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1708387200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924025524/thumbnail.png", "formType": "8-K"}, {"id": "0001104659-24-009109_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1706745600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465924009109/thumbnail.png", "formType": "8-K"}, {"id": "0000895345-24-000014_310158", "type": "Tender Offer/Acquisition Reports", "title": "SC 13G : Tender Offer/Acquisition Reports", "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions", "filingDate": 1705968000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001828253/000089534524000014/thumbnail.png", "formType": "SC 13G"}, {"id": "0001193125-24-009344_64978", "type": "Tender Offer/Acquisition Reports", "title": "SC 13D : Tender Offer/Acquisition Reports", "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities", "filingDate": 1705536000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001708493/000119312524009344/thumbnail.png", "formType": "SC 13D"}, {"id": "0001193125-24-006017_64978", "type": "Proxy Statements", "title": "DFAN14A : Proxy Statements", "description": "Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material", "filingDate": 1704844800000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001708493/000119312524006017/thumbnail.png", "formType": "DFAN14A"}, {"id": "0001193125-24-004544_64978", "type": "Proxy Statements", "title": "DFAN14A : Proxy Statements", "description": "Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material", "filingDate": 1704672000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001708493/000119312524004544/thumbnail.png", "formType": "DFAN14A"}, {"id": "0001104659-23-121671_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1701129600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923121671/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-23-036717_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1698969600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828023036717/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-23-111585_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1698278400000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923111585/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-23-027770_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1691366400000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828023027770/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-23-086030_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1690848000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923086030/thumbnail.png", "formType": "8-K"}, {"id": "0001140361-23-026845_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1685059200000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000114036123026845/thumbnail.png", "formType": "8-K"}, {"id": "0001193125-23-147049_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1684281600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312523147049/thumbnail.png", "formType": "8-K"}, {"id": "0001628280-23-015990_310158", "type": "Periodic Financial Reports", "title": "10-Q : Periodic Financial Reports", "description": "Quarterly report pursuant to Section 13 or 15(d)", "filingDate": 1683244800000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828023015990/thumbnail.png", "formType": "10-Q"}, {"id": "0001104659-23-050654_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1682553600000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923050654/thumbnail.png", "formType": "8-K"}, {"id": "0001193125-23-089525_310158", "type": "Proxy Statements", "title": "DEF 14A : Proxy Statements", "description": "Definitive proxy statements", "filingDate": 1680480000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312523089525/thumbnail.png", "formType": "DEF 14A"}, {"id": "0001628280-23-010404_310158", "type": "Annual Report to Shareholders", "title": "ARS : Annual Report to Shareholders", "description": "Annual report to security holders", "filingDate": 1680480000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828023010404/thumbnail.png", "formType": "ARS"}, {"id": "0001193125-23-089540_310158", "type": "Proxy Statements", "title": "DEFA14A : Proxy Statements", "description": "Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms", "filingDate": 1680480000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000119312523089540/thumbnail.png", "formType": "DEFA14A"}, {"id": "0001628280-23-005061_310158", "type": "Periodic Financial Reports", "title": "10-K : Periodic Financial Reports", "description": "Annual report pursuant to Section 13 and 15(d)", "filingDate": 1677196800000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000162828023005061/thumbnail.png", "formType": "10-K"}, {"id": "0001104659-23-015120_310158", "type": "Tender Offer/Acquisition Reports", "title": "SC 13G/A : Tender Offer/Acquisition Reports", "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions", "filingDate": 1675900800000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923015120/thumbnail.png", "formType": "SC 13G/A"}, {"id": "0001104659-23-009552_310158", "type": "Corporate Changes & Voting Matters", "title": "8-K : Corporate Changes & Voting Matters", "description": "Current report filing", "filingDate": 1675296000000, "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0000310158/000110465923009552/thumbnail.png", "formType": "8-K"}]}, "error": null}}